weill cornell medical college curriculum vitae...
TRANSCRIPT
WEILL CORNELL MEDICAL COLLEGE CURRICULUM VITAE FORM
(REQUIRED FORMAT)
Signature (required):
Version date: 9/1/18
A. GENERAL INFORMATION
Required Information:
Name: First, Middle, Last
James Bruce Bussel
Office address:
525 East 68th Street, P695, New York, NY 10065
Office telephone:
212‐746‐3474
Office fax:
212‐746‐5121
Home address:
115 East 67th Street, 9B, New York, NY 10065
Home telephone:
212‐734‐4346
Cell phone:
917‐291‐5091
Beeper:
n/a
Work Email: Personal Email:
Citizenship:
American
If not a U.S. Citizen, do you have:
Immigrant visa (green card)? Non‐immigrant Visa? Type:
Optional Information (not required but helpful):
Birth date:
07/16/1949
Birth place:
New York
Marital status:
Married
Race/Ethnicity:
Caucasian
B. EDUCATIONAL BACKGROUND
1. Academic Degree(s): B.A. and higher; institution name and location; dates attended; date of award. Expand the table as needed.
Degree (abbreviation)
Institution Name and Location
Dates attended Year Awarded
B.S. Yale University, Hartford 1968‐1971 1971
M.D. Columbia College of Physicians & Surgeons
1971‐1975 1975
2. Post‐doctoral training (include residency/fellowships): In chronological order beginning with post‐
doctoral training positions; include full titles, ranks and inclusive dates held. Expand the tables as needed.
Title Institution name and location Dates held
Intern in Pediatrics
Cincinnati Children's Hospital, Cincinnati, Ohio
1975‐76
Resident in Pediatrics
Cincinnati Children's Hospital, Cincinnati, Ohio
1976‐78
Fellow Pediatric Hematology/Oncology New York Hospital‐Cornell University Medical Center and Memorial Sloan‐Kettering Cancer Center, New York, New York
1978‐81
Chief Fellow
Pediatric Hematology/Oncology New York Hospital‐Cornell University Medical Center and Memorial Sloan‐Kettering Cancer Center, New York, New York
1980‐81
3. Continuing Medical Education Courses/Certificates
Certificate or Course Institution Name and Location Dates attended
ASH San Diego 12/1 – 12/5/2016
Pediatric Grand Rounds Weill Cornell Medical College, New York, NY
7/1/15 – 12/30/2016
Pediatric Professors’ Rounds Weill Cornell Medical College, New York, NY
7/1/15 – 6/30/16
4. Other Educational Experiences
Description Institution Name and Location Dates attended
C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE
1. Licensure: Every physician appointed to the Hospital staff, except interns, and aliens in the US via non‐immigrant visas, must have a New York State license or a temporary certificate in lieu of the license.
a. State Number Date of issue Date of last registration
New York
135038 July, 1978 July 1, 2016
b. If no license:
1. 1. Do you have a temporary certificate? Yes/No/NA
2. Have you passed the examination for foreign medical school graduates?
Yes/No/NA
c. DEA number (optional): AB1397632
d. NPI number (optional): 1063509156
2. Board Certification
Full Name of Board Certificate # Dates of Certification (mm/dd/yyyy) – Start and End Dates
American Board of Pediatrics
23166 09/06/1979
American Board of Pediatric Hematology/Oncology
451 01/11/1981
3. Malpractice Insurance
Do you have Malpractice Insurance? Yes / No / Anticipated / N/AName of Provider: MCIC Premiums paid by (choose one):
Self Group (name): Institution (name): Weill Cornell Medicine
D. PROFESSIONAL POSITIONS AND EMPLOYMENT
1. Academic positions (teaching and research)
Title Institution name and location Dates held
Instructor in Pediatrics
Cornell University Medical College, New York, New York
1981‐82
Assistant Professor of Pediatrics
Cornell University Medical College, New York, New York
1982‐88
Associate Professor of Pediatrics
Weill Medical College of Cornell University
1988‐2000
Professor of Pediatrics Weill Medical College of Cornell University
2000‐Present
Professor of Pediatrics in Obstetrics and Gynecology
Weill Medical College of Cornell University
2000‐Present
Professor of Pediatrics in Medicine Weill Medical College of Cornell University, New York
2004‐Present
2. Hospital positions (e.g., attending physician)
Title Institution name and location Dates held
Attending Pediatrician
New York Presbyterian Hospital, New York
2000‐Present
Assistant Attending & Associate Attending
New York Presbyterian Hospital, New York
1981‐88 1989‐99
Associate Adjunct Attending Pediatrician
Memorial Hospital for Cancer and Allied Diseases, New York
1991‐Present
Associate Attending Pediatrician Lenox Hill Hospital 1989‐2014
3. Other Employment
Title Institution name and location Dates held
E. EMPLOYMENT STATUS (current or anticipated)
Name of Employer(s): Weill Cornell Medicine
Employment Status (choose one, delete the others): Part‐time Salaried by Cornell (60%)
F. INSTITUTIONAL/HOSPITAL AFFILIATION
1. Primary Hospital Affiliation: New York Presbyterian Hospital
2. Other Hospital Affiliations:
3. Other Institutional Affiliations:
G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES
CURRENT % EFFORT (%) Does the activity involve WCMC
students/researchers? (Yes/No) TEACHING 10 YesCLINICAL 60 No ADMINISTRATIVE 5 YesRESEARCH 25 Yes TOTAL 100%
FOR NEW WCMC FACULTY: IT IS VERY HELPFUL TO HAVE THIS TABLE REPEATED, SO THAT THE COMMITTEE OF REVIEW CAN SEE THE EXPECTED RESPONSIBILITIES AND EFFORT AT WCMC
WCMC ANTICIPATED % EFFORT (%) Does the activity involve WCMC
students/researchers? (Yes/No) TEACHING CLINICAL ADMINISTRATIVE RESEARCH TOTAL 100%
INSTITUTIONAL RESPONSIBILITIES
1. Teaching (e.g., specific teaching functions, courses taught, dates: For guidance refer to Teaching
Metrics table. Report your teaching activities in the 4 areas of teaching shown below. To provide a more detailed teaching report, use the Teaching Activities Report template or Educator Portfolio template (strongly encouraged). Refer to it here as an attachment (e.g., see attached), and attach it to the CV.
Didactic teaching: (e.g., lectures, continuing medical education courses, grand rounds, professional development programs, seminars, tutorials)
Columbia Hematology Grand Rounds SUNY Downstate Ped Grand Rounds Good Samaritan Hospital Grand Rounds
Dates 10/5/1610/26/16 1/18/17
Weill Cornell Pediatric Grand Rounds
4/4/17
Mentorship: (e.g., mentor for medical student, graduate student, resident, clinical or postdoctoral research fellow or junior faculty projects; service as graduate student thesis advisor or committee member)
Committee of Admissions
Dates 7/1/16 – 6/30/17
Clinical teaching: (e.g., teaching in the clinic or hospital including bedside teaching, teaching in the operating room, preceptor in clinic)
Hospital Rounds
Dates
Administrative teaching leadership role: (e.g., residency or fellowship director, course or seminar director or co‐director)
Dates
2. Clinical care (duties, dates: To document clinical activities use the table below or, to document
extensive clinical activities use the Clinical Portfolio template (strongly encouraged). Refer to it here as an attachment and attach it to the CV.
Clinical Activity; Clinical Program Development Dates
Director, Platelet Disorders Program
Ongoing
3. Research (duties, dates): Summarize research activities in the table below. Provide key
contributions, and annotate key grants and publications or use a Statement of Key Contributions. Refer to it here and attach it to the CV.
Research Activity / Key Contributions Dates
See Bibliography
4. Administrative Activities (duties, dates): Describe administrative activities in the table below. To
document administrative activities more extensively use a supplemental statement, refer to it here and attach it to the CV.
Administrative Activity Date
H. RESEARCH SUPPORT
Summarize Past Research Support:
1. R01 EB016041 (Balduini, Alessandra) 09/01/2015‐08/31/2016 National Institutes of Health In vitro bioreactors for platelet formation Grant project is looking for new tools to unravel pathogenesis and possible targets for new treatments of thrombocytopenia as part of development her bioreactor that will synthesize blood (and platelets) in vitro. NOTE: this is subcontract from Tufts University, PIs: Drs. Balduini and Kaplan. Role: Co‐investigator 2. U34 HL115015 (Bussel, James B) 02/15/2013‐01/31/2016National Institutes of Health Determining Optimum Medical Therapy for ITP NOTE: This is collaborative planning grant with 5 sites for the Steering Committee. Dr. Bussel acts as the PI for the group. The overall goal of this planning grant is to develop a clinical trial optimizing curative medical therapy of ITP. This trial has evolved into comparing the combination of dexamethasone with anti‐CD20 and MMF to dexamethasone and rituximab + placebo to see whether the addition of MMF leads to more patients with a lasting effect at 2‐5 years from initial treatment. 3. R01 HL96497 (Yazdanbakhsh, Karina) 08/10/2009 ‐ 07/31/2013 National Institutes of Health Immunoregulatory Responses in Patients with ITP ‐ subcontract with NY Blood Center Study of the effect of TPO agents on Regulatory T cells NOTE: This is a subaward. Role: co‐investigator 4. 2U01 HL072196 (Bussel, James B) 09/01/2002 ‐ 08/31/2014 National Heart, Lung, & Blood Institute Novel Therapies in Hemostasis and Transfusion 5. U01 HL072268 (Bussel, James B) 09/01/2007‐08/31/2014 National Heart, Lung, & Blood Institute RING: Resolving Infection in Neutropenia with Granulocytes: High Dose Granulocyte Transfusions for the Treatment of Infection Study focuses on investigation of the treatment of infection in neutropenia. 6. 60029542 (Zehnder, James/Bussel, James B) 04/16/2012‐04/15/2014 GlaxoSmithKline Genome‐wide gene expression profiling of patients with ITP receiving eltrombopag NOTE: this is collaborative clinical project that is funded by industry sponsor and managed through grant mechanism. For Current extramural and intramural research funding, provide the following for each award:
1. Source, amount, and duration of support (dates) 2. Name of Principal Investigator 3. Individual's role in project, including percentage (%) effort
Candidates are encouraged to annotate multi‐investigator grants to clarify their role on the project (PI, Site PI, Project leader, Core director, etc.) Current Research Support (duplicate table as needed):
Source Multiple clinical trials funded by Amgen, GSK, Prophylix Pharma, Boehringer Ingelheim, Protalex, Rigel.
Amount These funds provide payment based on patient accrual rates and do not require particular effort allocation.
Duration Varies Principal Investigator Yes Your Role in Project % Effort Varies
Source ICON1 – Boston Children’s Hospital Amount Duration 09/01/2013‐12/31/2017 Principal Investigator No Your Role in Project Subaward% Effort
I. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES i.e. ‐ Journal Reviewer, Editorial Boards, Study Sections, Invited Presentations
Activity / Responsibility Dates
International Committee of Thrombosis and Hemostasis: ‐ Perinatal Subcommitte, Co‐Chairman ‐ Platelet Immunology Subcommittee: Chairman Co‐Chairman
1988‐1990, 1998 ‐ 2002 1992 – 1995 1990‐1992, 1995 ‐ 2003
Reviewer for Blood, British Journal of Haematology, Haematologica, New England Journal of Medicine, Lancet, Lancet Haematology, Pediatric Blood & Cancer
Ongoing
J. PROFESSIONAL MEMBERSHIPS
Include medical and scientific societies.
Member/Officer/Fellow/Role Organization Dates
Member
American Society of Hematology 1984 ‐ Present
Member
European Hematology Association 2014 – Present
Member
The Spaet Thrombosis Coalition 2016‐Present
K. HONORS AND AWARDS
Name of award Date awarded
Dewitt Clinton Award Honoree - Masonic Toys for Tots Foundation Inc
2013
King Faisal International Prize for Medicine (the Arab Nobel Prize)
2012
Dacie Lectureship
2011
Canadian Blood Services Intramural Grant Competition Reviewer
2009
President, New York Society for the Study of Blood 2007‐9
22nd Ratnoff Professor of Hematology at Case Western 2008 Reviewer, NIH Clinical Hematology Special Emphasis Panel 2006
Reviewer, Thrasher Research Fund 2006 Inclusion in both the 3rd edition of America’s Top Doctors and Top Doctors: New York Metro Area
2003‐13
Selection as 1 of 15 representatives of American Society of Hematology for SPARKII 1/20/03
2003
Speaker, The Henry Kunkel Society 11th Annual Meeting, Kunkel Society Symposium, Rockefeller University, New York, New York
2003
Chairman of ITP Meeting to Discuss Splenectomy Sparing Strategy, Boca Raton, Florida
1998
Alpha Award of the American Blood Resources Association for Contributions in Immunohematology
1998
Honorary Chairman of Children’s Blood Foundation New Projects Group Event
1992
Abstract Reviewer for ASH Platelet Section 2000, 03, 05, 07, 11, 13, 16
Chair, Education Session on Platelets at ASH 2000
Chairman Corporate symposium on ITP at ASH (Super Friday)
1999‐2016
Speaker Education Session American Society Hematology: A. HIV-related Thrombocytopenia B. Fetal and Neonatal Immune Cytopenias C. ITP
1990 1994 1997,2000, 2001, 2004, 2007
Abstract Reviewer and Session Moderator Immunohematology Section of American Society of Hematology Meeting
1987
10th Edward Pratt Lecturer, Cincinnati Children's Hospital 1995
Invited Consultant of Canadian Pediatric ITP Group 1991‐2
Symposium Chairman, First Annual Meeting of American Society for Pediatric Hematology/Oncology
1990
Session moderator, Pediatric Research Meeting, Section on Neonatal Hematology, New Orleans
1997
Abstract Reviewer and Session Moderator Society of Pediatric Research, Hematology, Anaheim, California
1989
Co-Chairman of Blood Club Meeting Society of the Pediatric Research Society Anaheim California
1989
L. BIBLIOGRAPHY
Entries should follow standard journal format, listing all authors, complete titles and inclusive pagination. Please also provide a URL to each of your published works as found in a publicly available digital database such as PubMed or My Bibliography, which are maintained by the US National Library of Medicine. Publications also may be annotated here (or in the Key Contributions Statement) to indicate the role of the candidate, where appropriate. This should be considered for co‐first authorship, co‐senior authorship, and in publications in which the candidate played an important role (leadership of a site, or methodology, etc.) that may not be apparent from the author order. Number the entries and put your name in bold type. The listings must be organized in chronological order. Use the following categories:
1. Articles in professional peer‐reviewed journals
2. Reviews
3. Books
4. Chapters
5. Other (media, DVD’s, etc.)
6. Abstracts: Optional, list 10‐20 best or most recent only.
7. Presentations: Optional, other than invited. List 10‐20 best or most recent only.
8. In review: manuscripts submitted or in preparation – list separately.
Peer-Reviewed Journal Articles:
1. Markus, G, McClintock, D., Bussel, J. B. : Allosteric studies with aspartate transcarbamylase. J Biol Chem,1971; 246:3:762-771. https://www.ncbi.nlm.nih.gov/pubmed/5542688
file:///Users/jbussel/Desktop/CV/JB CV Articles/Markus J Biological Chem 71 Conformational Changes in Aspartate Transcarbamylase.pdf
2. Bussel, J., Miller, S., Hilgartner, M. W., O'Reilly, Kempin, S., Miller, D.R. and Pollack, M.: Transient familial
occurrence of the lupus-like anticoagulant in 3 members of a family with A11B35D44 haplotype. Amer J Ped Hem/Onc, Fall, 1983; 5(3):275-278. https://www.ncbi.nlm.nih.gov/pubmed/6414325
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel AJPHO 83 transient appearance of lupus anticoagulant in 3 family members.pdf
3. Bussel, J. B., Kimberly, R. P., Inman, R. D., Cunningham-Rundles, C., Smithwick, E., Schulman, I., Cheung, N.,
O'Malley, J., Barandun, S. and Hilgartner, M. W.: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood, 1983; 62(2):480-486. https://www.ncbi.nlm.nih.gov/pubmed/6191803
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Blood 83 Ivig trtmnt of chronic ITP.pdf
4. Bussel, J. B., Lalezari, P., Hilgartner, M. W., O'Malley, J. and Barandun, S.: Reversal of autoimmune neutropenia
of infancy with intravenous gammaglobulin. Blood, 1983; 62(2):398-400.
https://www.ncbi.nlm.nih.gov/pubmed/6191800 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Blood 83 Reversal of neutropenia with ivig in autoimune neutropenia of infancy.pdf
5. Bussel, J. B., Schulman, I., Hilgartner, M. W. and Barandun, S.: Intravenous use of gammaglobulin in the treatment
of chronic immune thrombocytopenic purpura as a means to defer splenectomy. J Ped, 1983; 103(4):651-654.
https://www.ncbi.nlm.nih.gov/pubmed/6684679 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel J Peds 83 IV use of gammaglobulin in treatment of ITP to defer splenectomy.pdf
6. Bussel, J. B., Steinherz, P. G., Miller, D. R., and Hilgartner, M. W.: Heparin like anticoagulant in an 8 month old
with acute monoblastic leukemia. Amer J Hem, 1984; 16:83-90. https://www.ncbi.nlm.nih.gov/pubmed/6582779
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 84 AJH heparin-like anticoagulant in an 8 month old with acute monoblastic leukemia.pdf
7. Kimberly, R. P., Salmon, J. E., Bussel, J. B., Crow, M. K. and Hilgartner, M.W.: Modulation of mononuclear
phagocyte function by intravenous gammaglobulin. J Immunol, 1984; 132(2):745.
https://www.ncbi.nlm.nih.gov/pubmed/6228600 file:///Users/jbussel/Desktop/CV/JB CV Articles/Kimberly J of Immun 84 Modulation of mononuclear phagocyte function by ivig.pdf
8. Bussel, J. B.and Hilgartner, M.W.: The use and mechanism of action of intravenous immunoglobulin in the
treatment of immune hematologic disease. Br J Haemat, 1984; 56:1-7.
https://www.ncbi.nlm.nih.gov/pubmed/6367804 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 84 BJH The use and mechanism of action of IVIG in tx of immune haematologic disease.pdf
9. Kimberly, R. P., Inman, R. D., Bussel, J. B., Polk, J. R. and Hilgartner, M.W.: Modulation of mononuclear
phagocyte system function and circulating immune complexes by lyophilized concentrates in patients with classic hemophilia. Clinical Immunology and Immunopathology, 1984; 31:321-330.
https://www.ncbi.nlm.nih.gov/pubmed/6424990 file:///Users/jbussel/Desktop/CV/JB CV Articles/Kimberly Clin Immun & Immunopath 84 Modulation of mononuclear phagocyte system function.pdf
10. Bussel, J. B., Goldman, A., Imbach, P., Schulman, I., and Hilgartner, M.W.: Treatment of acute ITP of
childhood with intravenous infusions of gammaglobulin. J. Peds. , 1985; 106(6):886-890.
https://www.ncbi.nlm.nih.gov/pubmed/2582107 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel J Peds 85 Trtmnt of acute itp of childhood with ivig.pdf
11. Lachiewicz, P. F., Inglis, A. E., Insall, J. N., Sculco, T. P., Bussel, J. B., and Hilgartner, M. W.: Total knee
arthroplasty in hemophilia. The Journal of Bone and Joint Surgery, 1985; 67-A (9):1361-1366.
https://www.ncbi.nlm.nih.gov/pubmed/3935651 file:///Users/jbussel/Desktop/CV/JB CV Articles/Lachiewicz J of Bone & Joint Surgery 85 - Total Knee arthroplasty in hemophilia.pdf
12. Porges, A., Bussel, J., Kimberly, R., Schulman, I., Pollack, M., Pandey, J., Barandun, S. and Hilgartner,
M.: Elevation of platelet associated antibody levels in patients with chronic idiopathic thrombocytopenic purpura expressing the B8 and/or DR3 allotypies. Tissue Antigens, 1985; 26:132-137.
https://www.ncbi.nlm.nih.gov/pubmed/3877351 file:///Users/jbussel/Desktop/CV/JB CV Articles/Porges 85 Tissue Antigens - elevation of plt associated antibody levels in pts w chronic ITP.pdf
13. Bussel, J., Pahwa, S., Porges, A., Cunningham-Rundles, S., Koziner, B., Morell A. and Barandun, S.: Correlation
of in vitro immunoglobulin production with outcome of IV gammaglobulin treatment of chronic ITP. J. Clin. Immunol., 1986; 6(1):50-56. https://www.ncbi.nlm.nih.gov/pubmed/2420817
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel J Clin Imm 86 Correlation of in vitro antibody synthesis with outcome of ivig trmnt.pdf
14. Clarkson, S. B., Kimberly, R. P., Valinsky, J.E., Witmer, M.D., Bussel, J.B., Nachman, R.L., and Unkeless,
J.C.: Blockade of clearance of immune complexes by an anti-Fc receptor monoclonal antibody. J.Experimental Medicine , 1986; 164(2):474-489. https://www.ncbi.nlm.nih.gov/pubmed/2941515
file:///Users/jbussel/Desktop/CV/JB CV Articles/Clarkson J Exp Med 86 Blockade of clearance of immunce complexes by anti-fcy receptor.pdf
15. Clarkson, S. B., Bussel, J. B., Kimberly, R. P., Valinsky, J., Nachman, R. L. and Unkeless, J. C.: Treatment
of refractory immune thrombocytopenia purpura with an anti-Fc receptor antibody. New Eng Journal Medicine, 1986; 314(19):1236-1239. https://www.ncbi.nlm.nih.gov/pubmed/2939345
file:///Users/jbussel/Desktop/CV/JB CV Articles/Clarkson NEJM 86 Treatment of refractory ITP with an anti fcy receptor antibody.pdf
16. Bussel, J.B.: Lack of seroconversion to human T-cell lymphotropic virus, Type III, after intravenous immune
globulin. Transfusion , 1986; 26(4):399. https://www.ncbi.nlm.nih.gov/pubmed/3014693
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 86 Transfusion - lack of seroconversion to human t-cell lymphotropic virus type iii after ivig.pdf
17. Miller, C., Hilgartner, M., Harris M., Bussel, J. B., and Aledort L.: Concurrence and prevalence of hemophilia
A and von willebrand disease. Am J of Med Genetics,1986; 24:83-94.
https://www.ncbi.nlm.nih.gov/pubmed/3085499 file:///Users/jbussel/Desktop/CV/JB CV Articles/Miller AJ Med Genetics 86 Concurrence of VW & Hemophilia A.pdf
18. Bussel, J., Cunningham-Rundles, C. and Abraham, C.: Intravenous treatment of autoimmune hemolytic
anemia with very high dose gammaglobulin. Vox Sang,1986; 51(4): 264-9.
https://www.ncbi.nlm.nih.gov/pubmed/2432727 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 86 Vox Sang - IV tx of AIHA with very high dose gammaglobulin.pdf
19. Bussel, J. B. and Pham, L. C.: Intravenous treatment with gammaglobulin in adults with immune
thrombocytopenic purpura: Review of the literature. Vox Sanguinis, 1987; 52(3):206-211.
https://www.ncbi.nlm.nih.gov/pubmed/2440183 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 87 Vox Sang - IV tx with gammaglobulin in adults with ITP review of lit.pdf
20. Glassman, M. S., Rodriquez, R., Bussel, J., Spivak, Hilgartner, M.: Acute obstructive pancreatitis secondary to a
duodenal hematoma. Journal of Pediatric Gastroenterology and Nutrition, 1988;7: 619-621.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Glassman J Ped Gastro & Nutrition 88 Acute Obstructive Pancreatitis.pdf
21. Bussel, J., Pham, L. C., Aledort, L., and Nachman, R.: Maintenance treatment of adults with chronic refractory
immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin, Blood, 1988;
72(1):121-127. https://www.ncbi.nlm.nih.gov/pubmed/3134063 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Blood 88 Maintenance trtmnt chronic itp with IVIG.pdf
22. Bussel, J., Cunningham-Rundles, S., LaGamma, E. F., and Shellabarger, M.: Analysis of lymphocyte
proliferative response and subpopulations in very low birth weight infants during the first eight weeks of life. Pediatric Research, 1988; 23(5):457-462. https://www.ncbi.nlm.nih.gov/pubmed/3260370
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Peds Research 88 Analysis of Lymphocyte Proliferative Response.pdf
23. Bussel, J., Saal, S., and Gordon, B.: Combined plasma exchange and intravenous gammaglobulin in the
treatment of patients with refrac-tory immune thrombocytopenic purpura. Transfusion, 1988; 28(1):38-41.
https://www.ncbi.nlm.nih.gov/pubmed/3341064 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 88 Transfusion - Combined plasma exchange & IVGG in trtmnt of patients with refract ITP.pdf
24. Hollenberg, J.P.., Subak, L. L., Ferry, J. J., and Bussel, J. B.: Cost-effectiveness of splenectomy versus
intravenous gammaglobulin in the treatment of chronic immune thrombocytopenic purpura in childhood. J. Pediatrics, 1988; 112:530-9. https://www.ncbi.nlm.nih.gov/pubmed/2450983
file:///Users/jbussel/Desktop/CV/JB CV Articles/Hollenberg J Peds 88 cost-effectiveness of splenectomy.pdf
25. Bussel, J., Lalezari, P., and Fikrig, S. Intravenous treatment with gammaglobulin of autoimmune neutropenia of
infancy. J. Pediatrics, 1988; 112(2):298-301. https://www.ncbi.nlm.nih.gov/pubmed/2448443
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel J Peds 88 Iv treatment with y-globulin of autoimmune neutorpenia of infancy.pdf
26. Lynch, L., Bussel, J., Goldberg, J. D., Chitkara, U., Wilkins, I., McFarland, J., and Berkowitz, R. L.: The in utero
diagnosis and management of alloimmune thrombocytopenia. Prenatal Diagnosis, 1988; 8:329-331.
https://www.ncbi.nlm.nih.gov/pubmed/3405971 file:///Users/jbussel/Desktop/CV/JB CV Articles/Lynch Prenatal Diagnosis 88 In utero dx and mgmt of ait.pdf
27. Bussel, J., and Haimi, J. S. Isolated thrombocytopenia in patients infected with HIV: Treatment with
intravenous gammaglobulin. American Journal of Hematology, 1988; 28:79-84.
https://www.ncbi.nlm.nih.gov/pubmed/2456012 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 88 AJH - Isolated thrombocytopenia in pts with HIV.pdf
28. Posnett, D. N., Gottlieb, A., Bussel, J., Friedman, S., Chiorazzi, N., Li, Y., Szabo, P., Farid, N. and Robinson,
M.: T cell antigen receptor in autoimmunity. Journal of Immunology, 1988; 141(6):1963-1969.
https://www.ncbi.nlm.nih.gov/pubmed/3049797 file:///Users/jbussel/Desktop/CV/JB CV Articles/Posnett J Immuno 88 T cell antigen receptors in autoimmunity.pdf
29. Bussel, J. B., Berkowitz, R. L., McFarland, J. G., Lynch, L., Chitkara, U.: Antenatal treatment of neonatal
alloimmune thrombocytopenia. New England Journal of Medicine, 1988; 319:1374-1378.
https://www.ncbi.nlm.nih.gov/pubmed/3141811 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel NEJM 88 NAIT.pdf
30. Bussel, J., Berkowitz, R., McFarland J., Lynch L., Chitkara U.: In-utero platelet transfusion for alloimmune
thrombocytopenia. Lancet, 1988; 1307-08. https://www.ncbi.nlm.nih.gov/pubmed/2904026
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Lancet 88 In-Utero Plt tx for AIT.pdf
31. Engle, M. A., Fatica, N. S., Bussel, J. B., O'Loughlin, J.E., Snyder, M.S., Lesser, M.L.: Clinical trial of single-
dose intravenous gamma globulin in acute kawasaki disease. Amer J Dis Child., 1989; Vol 143:1300-1304.
https://www.ncbi.nlm.nih.gov/pubmed/2479260 file:///Users/jbussel/Desktop/CV/JB CV Articles/Engle Amer J Dis Child 89 - Clinical trial of single-dose IVGG in acute kawasaki disease.pdf
32. Bussel, J. B. Fitzgerald-Pedersen, J., Feldman, C.: Alternation of two doses of intravenous gammaglobulin in the
maintenance treatment of patients with immune thrombocytopenic purpura, Amer Journ Hem, 1990; 33:184-188.
https://www.ncbi.nlm.nih.gov/pubmed/1689103 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 90 AJH - Alternation of two doses of IVGG in the maintenance trtmnt of pts with ITP.pdf
33. Laver, J., Duncan, E., Abboud, M., Gasparetto, C., Sahdev, I., Warren, D., Bussel, J. B., Auld, P., O'Reilly,
R., Moore, M. A.: High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. J. Peds., 1990;Vol 116: 627-632.
https://www.ncbi.nlm.nih.gov/pubmed/1690796 file:///Users/jbussel/Desktop/CV/JB CV Articles/Laver J Peds 90 High levels of granulocyte in cord blood.pdf
34. Rabellino, E.M., Bussel, J.B.: Human Megakaryocytes. VII. Analysis of megakaryocytes for nuclear DNA
content distribution in whole marrow cell suspensions by flow cytometry. Experimental Hematology, 1990; Vol 18: 167-173. https://www.ncbi.nlm.nih.gov/pubmed/2303108
35. Chitkara, U., Bussel, J. B., Alvarez, M., Lynch, L., Meisel, R. L., Berkowitz, R. L.: High Dose IVGG: Does it
have a role in the treatment of severe erythroblastosis fetalis? Obstetric Gynecology, 1990; 76:703-8.
https://www.ncbi.nlm.nih.gov/pubmed/2120641 file:///Users/jbussel/Desktop/CV/JB CV Articles/Chitkara OBGYN 90 Does high dose ivig reat severe erythroblastosis fetalis.pdf
36. Samuels, P., Bussel, J. B., Braitman, L., Tomaski, A. Druzin, M., Mennuti, M. T., Cines, D.: Estimation of the
risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. New England J Medicine, 1990; 323(4):229-235. https://www.ncbi.nlm.nih.gov/pubmed/2366833
file:///Users/jbussel/Desktop/CV/JB CV Articles/Samuels NEJM 90 Esitmation of the risk of thrombocytopenia in the offspring of pregnant women with itp.pdf
37. Bharati S, Engle MA, Fatica NS, Bussel JB, Sulayman RF, Lev M, Lynfield J. The heart and conduction
system in acute Kawasaki disease: report of fraternal cases—one lethal, one relapsing. American Heart
Journal, 1990; 120(2): 359-65. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bharati Amer Heart Journal 90 - the heart & conduction system in acute Kawasaki diesease report on fraternal cases.pdf
38. Bussel, J. B., Graziano, J. N., Kimberly, R. P., Pahwa, S., Aledort, L.: IV anti-D treatment of immune
thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood, 1991; 77:1884-
1893. https://www.ncbi.nlm.nih.gov/pubmed/1850307 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Blood 91 IV anti d trtmnt in ITP.pdf
39. Bussel, J. B., Tanli, S. and Peterson, H. C.: Favorable neurological outcome in 7 cases of perinatal intracranial
hemorrhage due to immune thrombocytopenia. Amer J. Ped. Hem. Onc., 1991; 13(2):156-159.
https://www.ncbi.nlm.nih.gov/pubmed/2069223 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel AJPHO 91 Fav neurological outcome in 7 cases of perinatal ich due to ITP.pdf
40. McFarland, J. G., Aster R. H., Bussel, J. B., Gianopoulos, J. G., Derbes, R. S., Newman, P. J.: Prenatal diagnosis
of neonatal alloimmune thrombocytopenia using allele-specific oligonucleotide probes. Blood, 1991; 78(9):2276-
82. https://www.ncbi.nlm.nih.gov/pubmed/1932744 file:///Users/jbussel/Desktop/CV/JB CV Articles/McFarland Blood 91 Prenatal Dx of NAIT using allele-specific oligonucleotide probes.pdf
41. Bussel, J. B. Druzin, M. L., Cines, D. B., Samuels, P. Thrombocytopenia in pregnancy. Lancet, 1991; (2) 337-8.
https://www.ncbi.nlm.nih.gov/pubmed/1670891 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Lancet 91 Thrombocytopenia in pregnancy.pdf
42. Bussel, J. B., Kaplan, C., McFarland, J. G. and the Working Party on Neonatal Immune Thrombocytopenia of the
Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the ISTH.: Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. Thrombosis and Hemostasis, 1991; 65(5) 631-634. https://www.ncbi.nlm.nih.gov/pubmed/1871727
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Thromb & Hemos 91 Recommendations for eval & trtmnt of NAIT.pdf
43. Lynch, L., Bussel, J. B., McFarland, J. G., Chitkara, U., Berkowitz, R. L.: Antenatal treatment of alloimmune thrombocytopenia. Obstetrics & Gynecology, 1992; 80:67-71. https://www.ncbi.nlm.nih.gov/pubmed/1603500
file:///Users/jbussel/Desktop/CV/JB CV Articles/Lynch OBGYN 92 antenatal treatment of AIT.pdf
44. Soubrane, C., Tourani, J. M., Visonneau, A. S., Beldjord, V. K., Israel-Biet, D., Mouawad, Bussel, J. B., Weil, M.,
Khayat, D.: Biologic Response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood, 1993; 81(1):15-19.
https://www.ncbi.nlm.nih.gov/pubmed/8093346 file:///Users/jbussel/Desktop/CV/JB CV Articles/Soubrane Blood 93 Resopnse to anticd16 HIV ITP Pt.pdf
45. Scaradavou, A., Inglis, S., Peterson, P., Dunne, J., Chervenak, F., and Bussel, J.: Suppression of erythropoiesis
by intrauterine transfusions in hemolytic disease of the newborn: Use of erythropoietin to treat the late anemia. J Peds, 1993; 123:279-284. https://www.ncbi.nlm.nih.gov/pubmed/8345428
file:///Users/jbussel/Desktop/CV/JB CV Articles/Scaradavou 93 J Peds - Suppression of erythropoiesis by intrauterine txs in hemolytic disease of newborn.pdf
46. Dunkel, I., Bussel, J. B.: New developments in the treatment of neutropenia. Am J Dis in Childhood, 1993; 147:994-
1000. https://www.ncbi.nlm.nih.gov/pubmed/7689783 file:///Users/jbussel/Desktop/CV/JB CV Articles/Dunkel Am J Dis in Childhood 1993 New Developments in the Treatment of Neutropenia.pdf
47. Flores, G., Cunningham-Rundles, C., Newland, A., and Bussel, J. B.: Treatment of autoimmune hemolytic anemia
with intravenous gammaglobulin, Am J Hem.,1994; 44:237-242. https://www.ncbi.nlm.nih.gov/pubmed/8237993
file:///Users/jbussel/Desktop/CV/JB CV Articles/Flores 93 AJH - Efficacy of IVIG in tx of aiha.pdf
48. Sykora, C, and Bussel, J. B.: Coexistent congenital dyserythropoietic anemia and ectodermal dysplasia, Am J
Ped Hematology Oncology, 1994 16(2):173-176. https://www.ncbi.nlm.nih.gov/pubmed/8166371
file:///Users/jbussel/Desktop/CV/JB CV Articles/Sykora 94 AJPHO - Coexistent congenital dyserythropoietic anemia & ectodermal dysplasia.pdf
49. Adams, D. M., Bussel, J. B., Druzin, M. L.: Accurate intrapartum estimation of fetal platelet count by fetal scalp
sample smear. Am J Perinatology, 1994. 11(1):42-45. https://www.ncbi.nlm.nih.gov/pubmed/8155211
file:///Users/jbussel/Desktop/CV/JB CV Articles/Adams 94 AJ Perinatology - Accurate intrapartum estimation of fetal plt ct by fetal scalp sample smear.pdf
50. Schattner, E. and Bussel, J. B.: Mortality in immune thrombocytopenic purpura: Report of seven cases and
consideration of prognostic indicators. Am Journal of Hematology 46:120-126, 1994.
https://www.ncbi.nlm.nih.gov/pubmed/8172178 file:///Users/jbussel/Desktop/CV/JB CV Articles/Schattner 94 AJH - Mortality in ITP.pdf
51. Ali, A. A., Flombaum, C. D., Brochstein, Gillio, A. P., Bussel, J. B., Boulad, F.: Lactic acidosis and renal
enlargement at diagnosis and relapse of acute lymphoblastic leukemia. Journal of Pediatrics. 125:584-6. October
1994. https://www.ncbi.nlm.nih.gov/pubmed/7931878 file:///Users/jbussel/Desktop/CV/JB CV Articles/Ali 94 J of Peds - Lactic acidosis and renal enlargment at dxx and relapse of actue lymphoblastic leukemia.pdf
52. Scaradavou, A. and Bussel J.: Evans Syndrome: Results of a pilot study utilizing a multiagent treatment protocol.
American Journal of Pediatric Hematology-Oncology,17:290-295, 1995.
https://www.ncbi.nlm.nih.gov/pubmed/7583383 file:///Users/jbussel/Desktop/CV/JB CV Articles/Scaradavou JPHO 95 - Evans Syndrome.pdf
53. Paidas, M. J., Berkowitz, R. L., Lynch, L., Lockwood, C.J., Lapinski, R., McFarland, J. G., Bussel, J. B.: Alloimmune
thrombocytopenia: Fetal and neonatal losses related to cordocentesis. American Journal of Obstetrics and Gynecology 172:475-9, 1995. https://www.ncbi.nlm.nih.gov/pubmed/7856672
file:///Users/jbussel/Desktop/CV/JB CV Articles/Paidas AJOBGYN 1995 AIT losses related to cordocentesis.pdf
54. Leung, D.Y., Gioro, R., Kazemi, L., Flynn, P.A., Bussel, J.B.: Evidence for superantigen involvement in cardiovascular injury due to kawasaki syndrome. Journal of Immunology, 1995, 155:5018-5021.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Leung Journal of Immunology 1995 Evidence for Superantigen involvement in cardiovascular injury due to kawasaki syndrome.pdf
55. Lescale, K. B., Eddleman, K. A., Cines, B., Samuels, P.,, Tomaski, A., Lesser, M., McFarland, J. G. and Bussel,
J. B. Antiplatelet antibody testing in the thrombocytopenic pregnant women. American Journal of Obstetrics and Gynecology, 1996; 174(3): 1014-1018. https://www.ncbi.nlm.nih.gov/pubmed/8633628
file:///Users/jbussel/Desktop/CV/JB CV Articles/Lescale AJOBGYN 96 - antiplatelet antibody testing in thrombocytopenic pregnant women.pdf
56. Inglis, S. R., Lysikiewicz, A., Sonnenblick, A. L., Bussel, J., Chervenak, F. A.: Advantages of Larger Volume, Less
Frequent intrauterine red blood cell transfusions for maternal red cell alloimmunization. American Journal of Perinatology. Volume 13:1, p.27-33. January 1996. https://www.ncbi.nlm.nih.gov/pubmed/8645382
file:///Users/jbussel/Desktop/CV/JB CV Articles/Inglis 96 AJ Perinatology - Advantages of larger volume less frequent intrauterine red blood cell tx for maternal red cell alloimmunization.pdf
57. Abboud, R. M., Laver, J., Xu, F., Weksler, B., Bussel, J.B.: Serum levels of GM-CSF are elevated in patients with
thrombocytopenia. British Journal of Hematology, 1996; 92(2):486-488.
https://www.ncbi.nlm.nih.gov/pubmed/8603021 file:///Users/jbussel/Desktop/CV/JB CV Articles/Abboud 96 BJH - Serum levels of GMCSF are elevated in pts with thrombocytopenia.pdf
58. Pfaffenbach, G. Bussel, J. and Rubinstein, P.: A rapid genotype assay for PLA Haplotypes. Thrombosis Research,
81:3:353-365, 1996. https://www.ncbi.nlm.nih.gov/pubmed/8928093 file:///Users/jbussel/Desktop/CV/JB CV Articles/Pfaffenbach Thrombosis research 96 A Rapid Genotype Assay for PLA Haplotypes.pdf
59. Bussel J. B., Berkowitz R. L., Lynch L., Lesser M. L., Paidas M. J., Huang C. L., Mcfarland J. G.: Antenatal
management of alloimmune thrombocytopenia with intravenous gammaglobulin: a randomized trial of the addition of low dose steroids to IVIG in fifty-five maternal-fetal pairs. American Journal of Obstetrics and Gynecology, 1996,
174:5; 1414-1423. https://www.ncbi.nlm.nih.gov/pubmed/28140024 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel AJOBGYN 96 AIT with IVIG.pdf
60. Zunich, K., Bussel, J. B.: HIV-related ITP in clinical infectious disease. <Letter> Clinic Infec. Dis. 1996;22(6):1129-
30. file:///Users/jbussel/Desktop/CV/JB CV Articles/Zunich Clinical INfectious Diseases 1996 - HIV-related thrombocytopenia with IV anti D.pdf
61. Chang, M., Suen, Y. , Shen, V., Rosenthal, J., Bussel, J., Killen, R., Ellis, R., van de Ven, C., Cairo, M.S.:
Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production. Blood, vol.88(9), (November 1) 1996:pp 3354-
3362. https://www.ncbi.nlm.nih.gov/pubmed/8896400 file:///Users/jbussel/Desktop/CV/JB CV Articles/Chang Blood 96 reg of endogenous levels of thrombopoietin and IL11 during thrombocytopenia.pdf
62. Skupski, D., Bussel, J. B.: Further insights into the management of ITP in pregnancy. American Journal of
Obstetrics and Gynecology. <Letter> p1944-1946, June 1996. https://www.ncbi.nlm.nih.gov/pubmed/8678165
file:///Users/jbussel/Desktop/CV/JB CV Articles/Skupski AJOBGYN 96 Insights into ait in pregnancy.pdf
63. George, J.N., Woolf, S.H., Gary, M.P.H., Raskob, E., Wasser, Aledort, L.M., Ballem, P.J., Blanchette, V.S., Bussel.
J.B., Cines, D.B., Kelton, J.G., Lichtin, A.E., McMillan, R., Okerbloom, J.A., Regan, D.H., Warrier, I.: Idiopathic thrombocytopenic purpura: The recommendations of the American Society of Hematology. A practice guideline developed by explicit methods for the american society of hematology. Blood, 88:1:3-40, 1996.
https://www.ncbi.nlm.nih.gov/pubmed/8704187 file:///Users/jbussel/Desktop/CV/JB CV Articles/George Blood 96 ITP guidelines for ash.pdf
64. Prasad, V., Kim, I., Farrington, K., Bussel, J.B.: TTP following ITP in an HIV-positive boy. Amer. J. Pediatic Hem/Onc. 18(4):384-386;1996. https://www.ncbi.nlm.nih.gov/pubmed/8888747
file:///Users/jbussel/Desktop/CV/JB CV Articles/Prasad JPHO 96 TTP following ITP in HIV positive boy.pdf
65. Bussel, J.B. Skupski, D.W., McFarland, J.: Fetal Alloimmune Thrombocytopenia: Consensus and Controversy.
Journal of Maternal-Fetal Medicine. 5(5):281-292;1996. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel JMFM 1996 FAIT Consensus & Controversy.pdf
66. Christiaens, G.C.M.L. , Nieuwenhuis, K.H., Bussel, J.B.: Comparison of Platelet counts in first and second
newborns of mothers with immune thrombocytopenic purpura. Obstretrics Gynecology 1997;90:546-552.
https://www.ncbi.nlm.nih.gov/pubmed/9380314 file:///Users/jbussel/Desktop/CV/JB CV Articles/Christiaens OBGYN 97 Comparison of plt cts in 1st and 2nd newborns of mothers with ITP.pdf
67. Bussel, J.B.,Zabusky M.R., Berkowitz. R.L., McFarland, J.G.: Fetal Alloimmune Thrombocytopenia. New England
Journal of Medicine.1997;337(1):22-26. https://www.ncbi.nlm.nih.gov/pubmed/9203427
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel NEJM 97 FAIT.pdf
68. Scaradavou, A., Woo B., Woloski, B.M.R., Cunningham-Rundles, S., Ettinger, L., Aledort, L.M., Bussel, J.B.: Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients. Blood 1997;89(8):2689-2700. https://www.ncbi.nlm.nih.gov/pubmed/9108386
file:///Users/jbussel/Desktop/CV/JB CV Articles/Scaradavou Blood 97 IV anti D in 272 pts.pdf
69. Bussel, JB, Berkowitz, RL, and McFarland,JG: Mechanisms of IVIG Effect in Fetal Alloimmune Thrombocytopenia, 1997, Letter in British Journal of Haematology Vol. 98, 493-494. https://www.ncbi.nlm.nih.gov/pubmed/9266959
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 97 BJH - Maternal IVIG in Neonatal alloimmune thrombocytopenia.pdf
70. Warrier, I., Bussel, J.B., Valdez, L., Barbosa, J., Beardsley, D.S. and the Low-Dose IVIG Study Group: Safety and
Efficacy of Low-Dose Intravenous Immune Globulin (IVIG) Treatment for Infants and Children with Immune Thrombocytopenic Purpura. J. Ped Hem/Onc 1997;19(3): 197-201.
https://www.ncbi.nlm.nih.gov/pubmed/9201140 file:///Users/jbussel/Desktop/CV/JB CV Articles/Warrier JPHO 97 Safety of IVIG trtment for kids with ITP.pdf
71. Gururangan, S., McFarland, J.G., Douglas, C.B. , Skupski, D., Bussel, J.B.,:Bra(HPA-5b) Incompatibility causes
thrombocytopenia in neonates of mothers with immune thrombocytopenic purpura. J. Ped Hem/Onc
1998;20(3):202-206. https://www.ncbi.nlm.nih.gov/pubmed/9628430 file:///Users/jbussel/Desktop/CV/JB CV Articles/Gurarangan JPHO 98 HPA-5b incompatibility may cause thrombocytopenia in neonates of mothers with ITP.pdf
72. Gururangan S, Bussel JB. Combination immunotherapy for patients with refractory ITP or Evan’s Syndrome (ES).
Blood, 1998; 92(10) Supplement 1 (Part 2 of 2): 3345.
73. Marsh, E. Scott, RA, Granstein, RD, Aledo, A. and Bussel, JB. Blue papules and macules in a newborn. J Cutan Med Surg (Canada) , 1998;2(4):229-232. https://www.ncbi.nlm.nih.gov/pubmed/9678965
file:///Users/jbussel/Desktop/CV/JB CV Articles/Marsh 98 J Cutan Med Surg - Blue papules & macules in a newborn.pdf
74. Calleja, E. Klein, R., Bussel, J.B. Is It Necessary to Test Patients With Immune Thrombocytopenic Purpura (ITP)
for Seropositivity to HTLV-1? Am J Hem, 1999; 61:94-97. https://www.ncbi.nlm.nih.gov/pubmed/10367786
file:///Users/jbussel/Desktop/CV/JB CV Articles/Calleja AJH 99 Testing pts with ITP for Seropositivity to HTLV-1.pdf
75. Acharya, S and Bussel JB: Valproate: Hematologic Toxicities of Sodium Valproate. J. Ped. Hem. Onc.
2000;22(1):62-65. https://www.ncbi.nlm.nih.gov/pubmed/10695824 file:///Users/jbussel/Desktop/CV/JB CV Articles/Acharya JPHO 2000 - Hematologic Toxicity of Sodium Valproate.pdf
76. Corbacioglu, S., Bux, J., Welte, K., Gabrilove, JL., Konig, A. and Bussel, JB. Serum Granulocyte Colony-
Stimulating Factor Levels Are Not Increased In Patients with Autoimmune Neutropenia Of Infancy. J Peds.
2000;137(1):96-99. https://www.ncbi.nlm.nih.gov/pubmed/10891829 file:///Users/jbussel/Desktop/CV/JB CV Articles/Corbacioglu J Peds 00 Serum granulocyte colony-stimulating factor levels not increased in pts with autoimmune neutropenia.pdf
77. Karakantza M., Mouzaki A., Theodoropoulou M., Bussel JB and Maniatis A. Th1 and Th2 Cytokines in a Patient
with Evans Syndrome and Profound Lymphopenia. Brit J. Haematol. 2000;110:968-970.
https://www.ncbi.nlm.nih.gov/pubmed/11054090 file:///Users/jbussel/Desktop/CV/JB CV Articles/Karakantza BJH 00 Th1 and Th2 cytokines in pts with Evans and lymphopenia.pdf
78. Mora J, Dobrenis AM, Bussel JB, Aledo A. Spontaneous remission of congenital acute nonlymphoblastic leukemia
with normal karyotype in twins. Med Pediatr Oncol, 2000; 35(2): 110-3.
https://www.ncbi.nlm.nih.gov/pubmed/10918232 file:///Users/jbussel/Desktop/CV/JB CV Articles/Mora Medical & Pediatric Oncology 00 Spontaneous Remission of Congenital acute nonlymph leukemia with norm karyotype in twins.pdf
79. al-Jefri AH, Dror Y, Bussel JB, Freedman MH. Thrombocytopenia with absent radii: frequency of marrow
megakaryocyte progenitors, proliferative characteristics, and megakaryocyte growth and development factor responsiveness. Pediatr Hematol Oncol, 2000; 17(4): 299-306. https://www.ncbi.nlm.nih.gov/pubmed/10845228
file:///Users/jbussel/Desktop/CV/JB CV Articles/Al-Jefri PHO 00 TAR.pdf
80. Bussel JB., Mukherjee R., Stone AJ. A Pilot Study of rhu-IL 11 Treatment of Refractory ITP. Amer J Hematol.
2001;66(3):172-7. https://www.ncbi.nlm.nih.gov/pubmed/11279623 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel AJH 01 Pilot study of rhuIL-11 trtmnt of refrac ITP.pdf
81. Bussel JB., Kaufmann CP., Ware RE., Woloski BMR. Platelet Responses of Patients with Immune
Thrombocytopenic Purpura (ITP) to IV Anti-D and to IV Gammaglobulin: Do they Predict The Response to Subsequent Splenectomy? Am J Hematol 2001; 67(1):27-33. https://www.ncbi.nlm.nih.gov/pubmed/11279654
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel AJH 01 Do responses to IVIG and antiD predict response to splenectomy.pdf
82. Glade Bender J., Kaplan C., Porcelijn, ., McFarland J., Bussel JB. Anti-HPA-3A Induced Neonatal Alloimmune Thrombocytopenia: A Case Series and Review of the Literature. J Peds, 2001;138(6):862-867.
https://www.ncbi.nlm.nih.gov/pubmed/11391330 file:///Users/jbussel/Desktop/CV/JB CV Articles/Glade-Bender J Peds 01 Anti-HPA-3A induces severe NAIT.pdf
83. Newman GC, Novoa MV., Fodero EM., Lesser ML., Woloski BMR., Bussel JB. A dose of 75 ug/kg/d of i.v. anti-D Increases the Platelet Count More Rapidly and for a Longer Period of Time Than 50 ug/kg/d in Adults with Immune Thrombocytopenic Purpura. Brit J Hem, 2001;112:1076-1078. https://www.ncbi.nlm.nih.gov/pubmed/11298610
file:///Users/jbussel/Desktop/CV/JB CV Articles/Newman BJH 01 75 vs 50 anti D.pdf
84. Gaddipati S., Berkowitz RL., Lembet AA., Lapinski R., McFarland JG., Bussel JB. Initial Fetal Platelet Counts Predict the Response to Intravenous Gammaglobulin Therapy in Fetuses Affected by PLA1 Incompatibility. Amer J OB/GYN, 2001; 185(4):976-980. https://www.ncbi.nlm.nih.gov/pubmed/11641688
file:///Users/jbussel/Desktop/CV/JB CV Articles/Gaddipati Am JOBGYN 01 Initial fetal plt cts predict response to IVIG PLA1 incompatibility.pdf
85. Webber, NP, Mascarenhas, JO., Crow, MK., Bussel, JB., and Schattner, EJ. Functional Properties of lymphocytes in Idiopathic Thrombocytopenic Purpura. Human Immunology, 2001; 62:1346-1355.
https://www.ncbi.nlm.nih.gov/pubmed/11756003 file:///Users/jbussel/Desktop/CV/JB CV Articles/Webber Human Immunology 01 Functional Properties of Lymphocytes in ITP.pdf
86. Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune
gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. Journal of Clinical Immunology, 2001; 21(3): 193-9. https://www.ncbi.nlm.nih.gov/pubmed/11403226
file:///Users/jbussel/Desktop/CV/JB CV Articles/Gupta J Clin Immun 01 Cytokine Modulation in Kawasaki Disease.pdf
87. Roark J.H., Bussel J.B., Cines D.B., Siegel D.L.: Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood, 2002; 100(4):1388-98.
https://www.ncbi.nlm.nih.gov/pubmed/12149222 file:///Users/jbussel/Desktop/CV/JB CV Articles/Roark Blood 02 genetic analysis of autoantibodies in itp clonal expansion and somatic mutation.pdf
88. Cooper, N., Woloski, BMR., Fodero, EM., Novoa, M., Leber, M., Beer, JH. and Bussel, JB. Does treatment with intermittent infusions of IV anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura (ITP) to avoid splenectomy? Blood, 2002; 99(6):1922-1927.
https://www.ncbi.nlm.nih.gov/pubmed/11877261 file:///Users/jbussel/Desktop/CV/JB CV Articles/Cooper Blood 02 trtmnt with IV anti D avoid splenectomy.pdf
89. Gupta M., Johann-Liang R., Bussel JB., Gersony WM., Lehman, T. Elevated IgA and IgM antibodies in acute
Kawasaki disease. Cardiology, 2002; 97:180-182. https://www.ncbi.nlm.nih.gov/pubmed/12145471
file:///Users/jbussel/Desktop/CV/JB CV Articles/Gupta Cardiology 02 Elevated IgA and IgM in acute kawasaki disease.pdf
90. Ahmad A., Laborada G., Bussel J., and Nesin, M. Comparison of recombinant granulocyte colony-stimulating
factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants. J Pediatr Infect Dis., 2002; 21(11):1061-5. https://www.ncbi.nlm.nih.gov/pubmed/12442030
file:///Users/jbussel/Desktop/CV/JB CV Articles/Ahmad J Pediatr Infect Dis 02 trtment of preterm septic infants.pdf
91. Porcelijn L, Folman CC, de Haas M, Kanhai HH, Murphy MF, von dem Borne AE, Bussel JB. Fetal and neonatal
thrombopoietin levels in alloimmune thrombocytopenia. Pediatr Res. 2002 Jul;52(1):105-8
https://www.ncbi.nlm.nih.gov/pubmed/12084855 file:///Users/jbussel/Desktop/CV/JB CV Articles/Porcelijn Pediatric Research 02 Fetal & Neonatal thrombopoietin levels in AIT.pdf
92. Levy A., Cunningham-Rundles S, Mazza B, Simm M, Gorlick R, and Bussel JB. High P-glycoprotein mediated
export in refractory idiopathic thrombocytopenia purpura. Brit J Haem, 2002; 118(3): 836-8.
https://www.ncbi.nlm.nih.gov/pubmed/12181055 file:///Users/jbussel/Desktop/CV/JB CV Articles/Levy BJH 02 High P-glycoprotein-mediated export in pts with Hx of ITP.pdf
93. van den Oudenrijn S, Bruin M, Folman CC, Bussel J, de Haas M, von dem Borne AE. Three parameters, plasma
thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia. Br J Haematol, 2002; 117(2): 390-8.
https://www.ncbi.nlm.nih.gov/pubmed/11972523 file:///Users/jbussel/Desktop/CV/JB CV Articles/van den Oudenrijn BJH 02 3 parameters distinguish causes of congenital thrombocytopenia.pdf
94. Grodzicky T, Bussel JB, Elkon KB. Anti-platelet antibodies associated with Canale-Smith syndrome bind to the
same platelet glycoprotein complexes as those of idiopathic thrombocytopenic purpura patients. Clin Exp Immunol. 2002; 127(2): 289-92. https://www.ncbi.nlm.nih.gov/pubmed/11876752
file:///Users/jbussel/Desktop/CV/JB CV Articles/Grodzicky Clin Exp Immunol 02 antiplatelet antibodies associated with Canale-Smith syndrome.pdf
95. Schwartz, J., Eldor, A., Gillis, Giunta, A., S., Leber, M., and Bussel, JB. Long term follow-up after splenectomy
performed for immune thrombocytopenic purpura (ITP). Amer J Hem., 2003; 72:94-98.
https://www.ncbi.nlm.nih.gov/pubmed/12555211 file:///Users/jbussel/Desktop/CV/JB CV Articles/Schwartz AJH 03 Long term fu post splenectomy in ITP.pdf
96. Mitchell WB, Li J, Singh F, Michelson AD, Bussel J, Coller BS, French DL.: Two Novel Mutations in the aIIb
Calcium-Binding Domains Identify Hydrophobic Regions Essential for aIIbb3 biogenesis. Blood, 2003; 101: 2268-
2276. https://www.ncbi.nlm.nih.gov/pubmed/12424194 file:///Users/jbussel/Desktop/CV/JB CV Articles/Mitchell Blood 03 two novel mutations.pdf
97. Butros LJ, Bussel JB: Intracranial Hemorrhage in Immune Thrombocytopenic Purpura (ITP): A Retrospective
Analysis. Journal of Pediatric Hematology/Oncology, 2003; 25(8): 660-664.
https://www.ncbi.nlm.nih.gov/pubmed/12902925 file:///Users/jbussel/Desktop/CV/JB CV Articles/Butros JPHO 03 ICH in ITP.pdf
98. Gyongyossy-Issa M, Bussel JB, Carter CJ, Devine DV: Thrombopoiesis During ITP and HIV-ITP. Platelets, 2003;
14(5): 267-276. https://www.ncbi.nlm.nih.gov/pubmed/12944242 file:///Users/jbussel/Desktop/CV/JB CV Articles/Gyongyossy-Issa Platelets 03 Comparison of thrombopoiesis during ITP and HIV-ITP and response to IVIG.pdf
99. Fogarty PF, Rick ME, Zeng W, Risitano AM, Dunbar CE, Bussel JB. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clinical and Experimental Immunology, 2003;
133(3): 461-466. https://www.ncbi.nlm.nih.gov/pubmed/12930375 file:///Users/jbussel/Desktop/CV/JB CV Articles/Fogarty Clin Exp Immunol 03 Tcell receptor VB diversity in pts with ITP following splenec.pdf
100. Michel, M, Novoa, M, and Bussel, JB: Intravenous anti-D treatment of Immune Thrombocytopenic Purpura (ITP)
during pregnancy. Brit J. Haematology, 2003; 123(1): 142-146. https://www.ncbi.nlm.nih.gov/pubmed/14510957
file:///Users/jbussel/Desktop/CV/JB CV Articles/Michel BJH 03 IV anti D as treatment for ITP during pregnancy.pdf
101. Barnard D, Woloski M, Feeny D, McCusker P, Wu J, David M, Bussel J, Lusher J, Wakefield C, Henriques S,
Blanchette V; Canadian Children’s Platelet Study Group. Development of disease-specific health-related quality-of-life instruments in children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol,
2003; 25(1): 56-62. https://www.ncbi.nlm.nih.gov/pubmed/12544774 file:///Users/jbussel/Desktop/CV/JB CV Articles/Barnard JPHO 03 Development of Disease Specific HRQOL instrument for kids with ITP.pdf
102. Michel, M, Cooper, N, Jean, C, Frissora, C and Bussel, J.B.: Does Helicobacter pylori initiate or perpetuate immune
thrombocytopenic purpura? Blood, 2004; 103(3): 890-896. https://www.ncbi.nlm.nih.gov/pubmed/12920031
file:///Users/jbussel/Desktop/CV/JB CV Articles/Michel Blood 04 Hpylori in ITP.pdf
103. Cooper, N, Heddle, N, de Haas, M, Reid, M, Lesser, M, Fleit, H, Woloski, B.M.R., and Bussel, J.B.: IV anti-D and IVIG Achieve Acute Platelet Increases by Different Mechanisms: Modulation of Cytokine and Platelet Responses to IV anti-D by FcgRIIa and FcgRIIIa Polymorphisms. Brit J. Haematology, 2004; 124(4): 511-518.
https://www.ncbi.nlm.nih.gov/pubmed/14984503 file:///Users/jbussel/Desktop/CV/JB CV Articles/Cooper BJH 04 IV anti Dand IVIG.pdf
104. Onel, K and Bussel, JB. Adverse effects of estrogen therapy in a subset of women with ITP. J Thromb Haemost,
2004; 2(4): 670-671. https://www.ncbi.nlm.nih.gov/pubmed/15102024 file:///Users/jbussel/Desktop/CV/JB CV Articles/Onel 04 JTH adverse effects of estrogen therapy in ITP.pdf
105. Cooper, N, Stasi, R, Cunningham-Rundles, S, Feuerstein, M, Leonard, J, Amadori, S, and Bussel, JB.: The
efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenia purpura. Brit J. Haematology, 2004; 125(2): 232-239.
https://www.ncbi.nlm.nih.gov/pubmed/15059147 file:///Users/jbussel/Desktop/CV/JB CV Articles/Cooper BJH 04 Efficacy of B-cell depletion with antiCD20.pdf
106. Aledort, LM, Hayward, C, Chen, MG, Nichol, J, and Bussel, JB: "Prospective Screening of 205 Patients with ITP
Including Diagnosis, Serological Markers, and the Relationship of Platelet Counts, Endogenous Thrombopoietin, and Circulating Anti-Thrombopoietin Antibodies.” American Journal of Hematology, 2004; 76: 205-213.
https://www.ncbi.nlm.nih.gov/pubmed/15224353 file:///Users/jbussel/Desktop/CV/JB CV Articles/Aledort AJH 04 - 205 pts with ITP prospective screening.pdf
107. Bussel, JB, Eldor, A, Kelton, J, Varon, D, Brenner, B, Gillis, S, Angiolillo, A, Kulkarni, R, Abshire, T, Kelleher, J,
and the IGIV-C in ITP Study Group. IGIV-C, a novel intravenous immunoglobulin: Evaluation of safety, efficacy, mechanisms or action, and impact on quality of life. Thrombosis and Hemostasis, 2004; 91: 771-8.
https://www.ncbi.nlm.nih.gov/pubmed/15045139 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Thromb & Hemos 04 IGIV-C.pdf
108. Levy AS, Bussel J. Immune thrombocytopenic purpura: investigation of the role of cytomegalovirus infection. Br J Haematol, 2004; 126(4): 622-3. https://www.ncbi.nlm.nih.gov/pubmed/15287958
file:///Users/jbussel/Desktop/CV/JB CV Articles/Levy BJH 04 ITP role of CMV.pdf
109. Cines DB, Bussel JB, McMillan RB, Zehnder JL. Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program), 2004; 390-406. https://www.ncbi.nlm.nih.gov/pubmed/15561694
file:///Users/jbussel/Desktop/CV/JB CV Articles/Cines ASH Ed Prog 05 Congenital and Acquired Thrombocytopenia.pdf
110. Wang, J, Wiley, J, Luddy, R, Feuerstein, M, Bussel, JB. Chronic immune thrombocytopenia purpura (ITP) in
children: Assessment of rituximab treatment. Journal of Peds, 2005; 146(2): 217-221.
https://www.ncbi.nlm.nih.gov/pubmed/15689912 file:///Users/jbussel/Desktop/CV/JB CV Articles/Wang Journal of Peds 05 Chronic ITP in kids assessment of ritux.pdf
111. Curtis BR, Bussel JB, Manco-Johnson MJ, Aster RH, McFarland JG. Fetal and neonatal alloimmune
thrombocytopenia in pregnancies involving in vitro fertilization: a report of four cases. Am J of OBGYN, 2005;
192(2): 543-547. https://www.ncbi.nlm.nih.gov/pubmed/15696000 file:///Users/jbussel/Desktop/CV/JB CV Articles/Curtis AJOBGYN 05 F and NAIT in pregnancy with invitro.pdf
112. Davoren A, Bussel J, Curtis BR, Moghaddam M, Aster RH, McFarland JG. Prospective evaluation of a new platelet
glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol, 2005; 78(3): 193-7. https://www.ncbi.nlm.nih.gov/pubmed/15726595
file:///Users/jbussel/Desktop/CV/JB CV Articles/Davoren AJH 05 Eval of GP Assay PakAuto in Dx of AITP.pdf
113. Bussel, J.B., Zacharoulis, S, Kramer, K, McFarland, J, Pauliny, J, Kaplan, C, and the Neonatal Alloimmune
Thrombocytopenia Registry Group: Clinical and Diagnostic Features of Neonatal Alloimmune Thrombocytopenia: Comparison to Non-Immune Cases of Thrombocytopenia. Pediatric Blood & Cancer, 2005; 45(2): 176-183.
https://www.ncbi.nlm.nih.gov/pubmed/15828027 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Peds Blood and Cancer 05 Comparison of NAIT to non-immune thrombocytopenia.pdf
114. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML,
Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006; 107: 2639-2642. https://www.ncbi.nlm.nih.gov/pubmed/16352811
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bennett Blood 06 Prospective phase 1 2 study of ritux in children with ITP.pdf
115. Cines D, Bussel J. How I Treat Idiopathic Thrombocytopenic Purpura (ITP). Blood, 2005; 106: 2244-2251.
https://www.ncbi.nlm.nih.gov/pubmed/15941913 file:///Users/jbussel/Desktop/CV/JB CV Articles/Cines Blood 05 How I Treat ITP.pdf
116. Michel M, Kreidel F, Chapman ES, Zelmanovic D, Bussel JB. Prognostic relevance of large-platelet counts in
patients with immune thrombocytopenic purpura. Haematologica, 2005; 90(12): 1715-6.
https://www.ncbi.nlm.nih.gov/pubmed/16330456 file:///Users/jbussel/Desktop/CV/JB CV Articles/Michel Haematologica 05 relevance of large platelets in ITP.pdf
117. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for
refractory immune thrombocytopenic purpura. Am J Heme, 2006; 81(1): 19-25.
https://www.ncbi.nlm.nih.gov/pubmed/16369979 file:///Users/jbussel/Desktop/CV/JB CV Articles/Provan AJH 06 Efficacy of mmf for refrac ITP.pdf
118. Berkowitz RL, Kolb EA, McFarland JG, Wissert M, Primani A, Lesser M, and Bussel JB. Parallel randomized trials
of risk-based therapy for fetal alloimmune thrombocytopenia. Obstetrics & Gyencology, 2006; 107(1): 91-96.
https://www.ncbi.nlm.nih.gov/pubmed/16394045 file:///Users/jbussel/Desktop/CV/JB CV Articles/Berkowitz OBGYN 06 Parallel Trials for FAIT.pdf
119. Pergolizzi RG, Jin G, Chan D, Pierre L, Wagner DD, Lenting PJ, Denis CV, Bussel JB, Ferris B, Leopold PL and
Crystal RG. Correction of a Murine Model of von Willebrand Disease by Gene Transfer. Blood, 2006; 108: 862-
869. https://www.ncbi.nlm.nih.gov/pubmed/16638935 file:///Users/jbussel/Desktop/CV/JB CV Articles/Pergolizzi Blood 06 Correction of murine model of VW disease.pdf
120. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS,
Wiznitzer I, Kelly R, Chien-Feng C, Nichol JL. Effect of a Novel Thrombopoiesis-Stimulating Protein (AMG 531) in Chronic Immune Thrombocytopenic Purpura. NEJM, 2006; 355: 1672-1681.
https://www.ncbi.nlm.nih.gov/pubmed/17050891 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel NEJM 06 AMG 531.pdf
121. Ward MJ, Pauliny J, Lipper EG, Bussel JB. Long-Term Effects of Fetal and Neonatal Alloimmune
Thrombocytopenia and Its Antenatal Treatment on the Medical and Developmental Outcomes of Affected Children. Am J Perinatology, 2006; 23: 487-492. https://www.ncbi.nlm.nih.gov/pubmed/17094038
file:///Users/jbussel/Desktop/CV/JB CV Articles/Ward AJ Perinatology Long-term effects of NAIT treatment.pdf
122. Berkowitz RL, Bussel JB, and McFarland JG. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet
Gynecol, 2006; 195(4): 907-13. https://www.ncbi.nlm.nih.gov/pubmed/16875656
file:///Users/jbussel/Desktop/CV/JB CV Articles/Berkowitz AJOBGYN 06 AIT state of the art.pdf
123. Bussel JB, Hanna K, and the IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based
intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura (ITP). American Journal of Hematology, 2007; 82: 192-198.
https://www.ncbi.nlm.nih.gov/pubmed/17109385 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel AJH 07 Safety and Tolerability for IVIG high rate infusion.pdf
124. Scaradavou A, Cunningham-Rundles S, Ho JL, Folman C, Doo H, and Bussel JB. Superior effect of intravenous
anti-D compared to IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. American Journal of Hematology, 2007; 82(5): 335-41.
https://www.ncbi.nlm.nih.gov/pubmed/17154377 file:///Users/jbussel/Desktop/CV/JB CV Articles/Scaradavou AJH 07 anti-D IVIG in HIV thrombocytopenia.pdf
125. Giulino LB, Bussel JB, Neufeld EJ, and the Pediatric and Platelet Immunology Committees of the TMH clinical trial
network. Treatment with Rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics, 2007; 150(4): 338-44. https://www.ncbi.nlm.nih.gov/pubmed/17382107
file:///Users/jbussel/Desktop/CV/JB CV Articles/Giulino J Peds 07 Ritux trtmnt in hem disorders in children.pdf
126. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-
related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes, 2007; 5: 11. https://www.ncbi.nlm.nih.gov/pubmed/17316442
file:///Users/jbussel/Desktop/CV/JB CV Articles/Mathias HQLO 07 disease specific measure of HQOL in ITP adults.pdf
127. Page LK, Psaila B, Provan D, Hamilton JM, Jenkins JM, Elish AS, Lesser ML, Bussel JB. The ITP Bleeding Score
(IBLS): Assessment of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP). British Journal of Haematology, 2007; 138(2): 245-8. https://www.ncbi.nlm.nih.gov/pubmed/17542983
file:///Users/jbussel/Desktop/CV/JB CV Articles/Page BJH 07 ITP Bleeding Score.pdf
128. Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C, and Bussel JB. An antepartum treatment trial without early cordocentesis for “standard risk” alloimmune thrombocytopenia: A randomized controlled trial. Obstetrics & Gynecology, 2007; 110 (2 Pt 1): 249-55. https://www.ncbi.nlm.nih.gov/pubmed/17666597
file:///Users/jbussel/Desktop/CV/JB CV Articles/Berkowitz Obst & Gyn 07 Antepartum trtmnt for SR AIT.pdf
129. Herve M, Isnardi I, Ng YS, Bussel JB, Ochs HD, Cunningham-Rundles C, Meffre E. CD40 ligand and MHC class
II expression are essential for human peripheral B cell tolerance. J Exp Med, 2007; 204(7): 1583-93.
https://www.ncbi.nlm.nih.gov/pubmed/17562816 file:///Users/jbussel/Desktop/CV/JB CV Articles/Herve J Exp Med 07 CD40 ligand & MHC B cell tolerance.pdf
130. Tarantino MD, Bussel JB, Cines DB, McCrae KR, Gernsheimer T, Liebman HA, Wong WY, Kulkarni R, Grabowski E, McMillan R. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood, 2007; 109(12): 5527. https://www.ncbi.nlm.nih.gov/pubmed/17554071
file:///Users/jbussel/Desktop/CV/JB CV Articles/Tarantino Blood 07 IVH anti-D for ITP.pdf
131. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multi-agent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood, 2007; 110(10): 3526-31.
https://www.ncbi.nlm.nih.gov/pubmed/17698634 file:///Users/jbussel/Desktop/CV/JB CV Articles/Boruchov Blood 07 Maintenance therapy for refrac ITP.pdf
132. Zhang L, Radigan L, Salzer U, Behrens T, Grimbacher B, Diaz G, Bussel JB, and Cunningham-Rundles C.
Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in Common Variable Immunodeficiency: Clinical and Immunologic Outcomes in Heterozygotes. Journal of Allergy and Clinical Immunology, 2007; 120: 1178-85. https://www.ncbi.nlm.nih.gov/pubmed/17983875
file:///Users/jbussel/Desktop/CV/JB CV Articles/Zhang J Allergy Clin Imm 07 TACI CVI.pdf
133. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag, an Oral Platelet Growth Factor, for the Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura. NEJM, 2007; 357(22): 2237-47.
https://www.ncbi.nlm.nih.gov/pubmed/18046028 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel NEJM 07 Eltrombopag ITP.pdf
134. Bussel JB, Tarantino MD, Nalysnyk L, Fahrbach K, Sercus B, Genereux M, and Sinclair C. Efficacy and safety of
intravenous rhesus 0 human immune globulin (IV RhIG) and standard polyclonal intravenous immune globulins (IVIG) in the treatment of immune thrombocytopenic purpura: A systematic review. U.S. Hematology Touch Briefings, 2007; 3-7.
135. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with
chronic immune thrombocytopenic purpura. American Journal of Hematology, 2008; 83(2): 150-4.
https://www.ncbi.nlm.nih.gov/pubmed/17722072 file:///Users/jbussel/Desktop/CV/JB CV Articles/McMillan AJH 08 QOL in adults with ITP.pdf
136. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, George JN, et al. Efficacy of romiplostim in patients
with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet, 2008; 371:
395-403. https://www.ncbi.nlm.nih.gov/pubmed/18242413 file:///Users/jbussel/Desktop/CV/JB CV Articles/Kuter Lancet 08 Nplate.pdf
137. Patel VL, Schwartz J, Bussel JB. The Effect of Blocking the CD40ligand Pathway in Patients with Immune
Thrombocytopenic Purpura. British Journal of Haem, 2008; 141: 545-48.
https://www.ncbi.nlm.nih.gov/pubmed/18341638 file:///Users/jbussel/Desktop/CV/JB CV Articles/Patel BJH 08 Effect of anti-CD40 in ITP.pdf
138. Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, Wu A, Bussel JB, George JN, McMIllan R, Wysocki
DK, Nichol JN. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health and Quality of Life Outcomes, 2008; 6:13.
https://www.ncbi.nlm.nih.gov/pubmed/18261217 file:///Users/jbussel/Desktop/CV/JB CV Articles/Mathias HQLO 08 Impact of ITP on QOL.pdf
139. Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K. Defective circulating CD25 regulatory T cells
in patients with chronic immune thrombocytopenic purpura. Blood, 2008; 112(4): 1325-28.
https://www.ncbi.nlm.nih.gov/pubmed/18420827 file:///Users/jbussel/Desktop/CV/JB CV Articles/Yu Blood 08 CD25 T cells.pdf
140. Wasserstrom H, Bussel JB, Lim LCL, Cunningham-Rundles C. Memory B cells and Antibody to Pneumococcal
Vaccine in Splenectomized Subjects. J Immuno, 2008; 181(5): 3684-9.
https://www.ncbi.nlm.nih.gov/pubmed/18714044 file:///Users/jbussel/Desktop/CV/JB CV Articles/Wasserstrom Journal of Immunology 08 Memory B Cells.pdf
141. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper
N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura
(ITP) of adults and children: report from an international working group. Blood, 2009; 113(11): 2386-93.
https://www.ncbi.nlm.nih.gov/pubmed/19005182 file:///Users/jbussel/Desktop/CV/JB CV Articles/Rodeghiero Blood 09 Standardization of terminology.pdf
142. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury Db, Mayer
B, Stone N, Arning M. Eltrombopag Increases Platelet Counts and Reduces Bleeding During Treatment of Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Randomized, Double Blind, Placebo-controlled Study. Lancet, 2009; 373(9664): 641-8. https://www.ncbi.nlm.nih.gov/pubmed/19231632
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Lancet 09 Effect of eltrombopag.pdf
143. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of Mice and Men: an Open Label Pilot Study for Treatment of Immune Thrombocytopenic Purpura (ITP) by an Inhibitor of Syk. Blood, 2009; 113(14): 3154-60.
https://www.ncbi.nlm.nih.gov/pubmed/19096013 file:///Users/jbussel/Desktop/CV/JB CV Articles/Podolanczuk Blood 09 Of mice and men inhibitor of Syk.pdf
144. Bussel JB, Kuter D, Pullarkat VA, Lyons R, Guo M, Nichol J. Safety and efficacy of long-term treatment with
romiplostim in thrombocytopenic patients with chronic ITP. Blood, 2009; 113(10): 2161-71.
https://www.ncbi.nlm.nih.gov/pubmed/18981291 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Blood 09 Long-term romiplostim efficacy.pdf
145. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel
JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood, 2009; 113(6): 1231-40. https://www.ncbi.nlm.nih.gov/pubmed/18945961
file:///Users/jbussel/Desktop/CV/JB CV Articles/Stasi Blood 09 H pylori eradication.pdf
146. Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ; for the Pediatric Rituximab/ITP Study Group, the Glaser Pediatric Research Network. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood & Cancer, 2009; 52(2): 259-62. https://www.ncbi.nlm.nih.gov/pubmed/18937333
file:///Users/jbussel/Desktop/CV/JB CV Articles/Mueller Peds Blood Cancer 09 - Ritux follow up one year.pdf
147. DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus Causes Refractory Immune Thrombocytopenic Purpura.
British Journal of Haematology, 2009; Jun;146(1):104-12. https://www.ncbi.nlm.nih.gov/pubmed/19438507
file:///Users/jbussel/Desktop/CV/JB CV Articles/Dimaggio BJH 09 - CMV and ITP.pdf
148. Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, Edholm ES, Santini PA, Rath P, Chiu A, Cattalini M, Litzman J, Bussel JB, Huang B, Meini A, Riesbeck K, Cunningham-Rundles C, Plebani A, Cerutti A. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in
basophils. Nat Immunol. 2009 Aug;10(8):889-98. file:///Users/jbussel/Desktop/CV/JB CV Articles/Chen Immunology 09 - Immunoglobulin D enhances immune surveillance.pdf
149. Sharma G, Nesin M, Feuerstein M, Bussel JB. Maternal and Neonatal Characteristics Associated with Neonatal
Neutropenia in Hypertensive Pregnancies. American Journal of Perinatology, 2009; 26(9): 683-9.
https://www.ncbi.nlm.nih.gov/pubmed/19670129 file:///Users/jbussel/Desktop/CV/JB CV Articles/Sharma AJ Perinatology 09 - Maternal & Neonatal Characteristics - neonatal neutropenia.pdf
150. Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard J, Bussel JB. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Heme, 2009; 84(10): 661-65.
https://www.ncbi.nlm.nih.gov/pubmed/19731307 file:///Users/jbussel/Desktop/CV/JB CV Articles/Hasan AJH 09 Repeated courses of rituxan.pdf
151. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood, 2009; 114(23): 4777-83.
https://www.ncbi.nlm.nih.gov/pubmed/19767509 file:///Users/jbussel/Desktop/CV/JB CV Articles/Psaila Blood 09 - ICH in children with ITP 40 cases.pdf
152. Provan D, Stasi R, Newland A, Blanchette V, Bolton-Maggs P, Bussel JB, Chong B, Cines D, Gernsheimer T, Godeau B, Grainger J, Greer I, Hunt B, Imbach P, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter D. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010; 115(2):168-86. https://www.ncbi.nlm.nih.gov/pubmed/19846889
file:///Users/jbussel/Desktop/CV/JB CV Articles/Provan Blood 09 - international consensus report on ITP.pdf
153. He B, Santamaria R, Cunningham-Rundles C, Xu W, Puga I, Chen K, Cols M, Xiong H, Bussel JB, Chiu A, Puel A, Reichenbach J, Marodi L, Doffinger R, Vasconcelos J, Issekutz A, Krause J, Davies G, Li X, Grimbacher B, Plebani A, Meffre E, Picard C, Casanova JL, Cerutti A. TACI triggers immunoglobulin class switching via MyD88. Nature Immunology, 2010; 11(9): 836-45. https://www.ncbi.nlm.nih.gov/pubmed/20676093
file:///Users/jbussel/Desktop/CV/JB CV Articles/He 09 Nature Immunology - transmembrane activator TACI.pdf
154. Marks KM, Clarke RM, Bussel JB, Talal AH, Glesby MJ. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr, 2009; 52(5): 595-9.
https://www.ncbi.nlm.nih.gov/pubmed/19734800 file:///Users/jbussel/Desktop/CV/JB CV Articles/Marks 09 JAIDS - Risk factors for thrombocytopenia in HIV-infected persons.pdf
155. Peerschke El, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol, 2010;
148(4):638-45. https://www.ncbi.nlm.nih.gov/pubmed/19925495 file:///Users/jbussel/Desktop/CV/JB CV Articles/Peerschke 10 BJH Complement activation on platelets.pdf
156. Bussel JB, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, Tsaur FW, McFarland JG. Intracranial hemorrhage in alloimmune thrombocytopenia: Stratified management to prevent recurrence in the subsequent affected fetus. Am J OBGYN, 2010; 203(2): 135.e1-14. https://www.ncbi.nlm.nih.gov/pubmed/20494333
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel AJOG 10 ICH in AIT stratified mgmt to prevent recurrence.pdf
157. Kane I, Ragucci D, Shatat IF, Bussel JB, Kalpatthi R. Comparison of Intravenous Immune Globulin and High Dose Anti-D Immune Globulin as Initial Therapy for Childhood Immune Thrombocytopenic Purpura. Br J Haem, 2010;
149(1):79-83. https://www.ncbi.nlm.nih.gov/pubmed/20096011 file:///Users/jbussel/Desktop/CV/JB CV Articles/Kane 10 BJH - Comparison of IVIG and high dose anti D for childhood ITP.pdf
158. Vincent LM, Gilbert F, DiPace J, Dorward H, Ciccone C, Markello TC, Jeong A, Westbroek W, Bussel JB, Gahl WA, Huizing M. Novel 47.5-kb deletion in RAB27A results in severe Griscelli Syndrome type 2. Molecular Genetics and Metabolism, 2010; 101(1): 62-5. https://www.ncbi.nlm.nih.gov/pubmed/20591709
file:///Users/jbussel/Desktop/CV/JB CV Articles/Vincent Molecular genetics and metabolism 10 - Novel 47.5-kb deletion in RAB27A - Griscelli syndrome.pdf
159. Ruisi MM, Psaila B, Ward MJ, Villarica G, and Bussel JB. Stability of measurement of the immature platelet
fraction. Am J Heme, 2010; 85(8): 622-4. https://www.ncbi.nlm.nih.gov/pubmed/20658593
file:///Users/jbussel/Desktop/CV/JB CV Articles/Ruisi AJH 10 - Stability of measurement of IPF.pdf
160. Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K. Improved regulatory T cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood, 2010; 116(22): 4639-
45. https://www.ncbi.nlm.nih.gov/pubmed/20688957 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bao Blood 2010 - Improved treg cell activity in patients with chronic ITP treated with TPO agents.pdf
161. Cheng G, Saleh MN, Marcher C, Vesey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for
the management of chronic immune thrombocytopenia: a 6-month, randomized, phase III study (RAISE). Lancet, 2011; 377(9763): 393-402. https://www.ncbi.nlm.nih.gov/pubmed/20739054
file:///Users/jbussel/Desktop/CV/JB CV Articles/Cheng Lancet 11 - Eltrombopag for management of chronic ITP - RAISE.pdf
162. Magallon J, Chen J, Rabbani L, Dangas G, Yang J, Bussel J, Diacovo T. Humanized mouse model of thrombosis
is predictive of the clinical efficacy of antiplatelet agents. Circulation, 2011; 123(3): 319-26.
https://www.ncbi.nlm.nih.gov/pubmed/21220740 file:///Users/jbussel/Desktop/CV/JB CV Articles/Magallon Circulation 2011 - Humanized Mouse Model of Thrombosis.pdf
163. Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarcia GO, Ruisi MM, Gernsheimer TB, Beer
JH, Bussel JB. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia (ITP). Blood, 2011; May 26;117(21):5723-32. https://www.ncbi.nlm.nih.gov/pubmed/21389318
file:///Users/jbussel/Desktop/CV/JB CV Articles/Barsam Blood 2011 Platelet production & platelet destruction.pdf
164. Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S. A
randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia (ITP). Blood, 2011; Jul 7;118(1):28-36. https://www.ncbi.nlm.nih.gov/pubmed/21502541
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Blood 2012 - Randomized double-blind study of romiplostim to determine safety and efficacy in children with ITP.pdf
165. Sarpatwari A, Bussel JB, Ahmed M, Erqou S, Semple JW, Newland AC, Bennett D, Pharoah P, Provan D. Single
nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. Hematology, 2011; Jul;16(4):243-8.
https://www.ncbi.nlm.nih.gov/pubmed/21756542 file:///Users/jbussel/Desktop/CV/JB CV Articles/Sarpatwari Hematology 2011 - single nucleotide polymorphism analyssi demosntrates a significant association of tumour necrosis factor-alpha.pdf
166. Ghanima W, Junker P, Hasselbalch HC, Boiocchi L, Geyer JT, Feng X, Gudbrandsdottir S, Orazi A, Bussel JB. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol. 2011 Oct;155(2):248-25. https://www.ncbi.nlm.nih.gov/pubmed/21902682
file:///Users/jbussel/Desktop/CV/JB CV Articles/Ghanima 2011 BJH Fibroproliferative activity in patients with ITP treated with TPO agents.pdf
167. Pacheco LD, Berkowitz RL, Moise KJ, Bussel JB, McFarland JG, Saade G. Fetal and Neonatal Alloimmune Thrombocytopenia: A Management Algorithm Based on Risk Stratification. Obstetrics and Gynecology, 2011; Nov;
118(5): 1157-1163. https://www.ncbi.nlm.nih.gov/pubmed/22015886 file:///Users/jbussel/Desktop/CV/JB CV Articles/Pacheco -Obstetrics and Gynecology 2011 - Fetal and NAIT.pdf
168. Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, Derevel T, Auzary C, Jaussaud R, Larroche C, Lequellec A, Ruivard M, Seve P, Smail A, Viallard JF, Godeau B, Hermine O, Michel M. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011 Nov;155(4):498-508.
https://www.ncbi.nlm.nih.gov/pubmed/21981575 file:///Users/jbussel/Desktop/CV/JB CV Articles/Gobert 2011 BJH - Efficacy and safety of rituximab in common variable immunodeficiency-associated cytopenias.pdf
169. Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011 Nov;9(11):2302-2310.
https://www.ncbi.nlm.nih.gov/pubmed/21920014 file:///Users/jbussel/Desktop/CV/JB CV Articles/Psaila JTH 2011 - Differences in plt function in pts with acute myeloid leukemia.pdf
170. Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood, 2011; 118(22): 5862-71. https://www.ncbi.nlm.nih.gov/pubmed/22123909
file:///Users/jbussel/Desktop/CV/JB CV Articles/Sanborn 2011 Blood - Phosphyorylation of the myosin IIA tailpiece regulates single myosin IIA molecule assocation with lytic granules to promote NK-cell cytotoxicity.pdf
171. Cines DB, Blajchman MA, High KA, Bussel JB; for the State-of-the Science Symposium Hemostasis-Thrombosis
Committee. Clinical trial opportunities in hemostasis and thrombosis: NHBLI State-of-the-science symposium. AJH, 2011; 87(2): 235-243. https://www.ncbi.nlm.nih.gov/pubmed/22120890
file:///Users/jbussel/Desktop/CV/JB CV Articles/Cines 2011 AJH - Clinical trial opportunities in hemostasis and thrombosis.pdf
172. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, Comerma L, Chorny A, Shan M, Xu W, Magri G, Knowles
DM, Tam W, Chiu A, Bussel JB, Serrano S, Lorente JA, Bellosillo B, Lloreta J, Juanpere N, Alameda F, Baró T, de Heredia CD, Torán N, Català A, Torrebadell M, Fortuny C, Cusí V, Carreras C, Diaz GA, Blander JM, Farber CM, Silvestri G, Cunningham-Rundles C, Calvillo M, Dufour C, Notarangelo LD, Lougaris V, Plebani A, Casanova JL, Ganal SC, Diefenbach A, Aróstegui JI, Juan M, Yagüe J, Mahlaoui N, Donadieu J, Chen K, Cerutti A. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol, 2011; 13(2): 170-80. https://www.ncbi.nlm.nih.gov/pubmed/22197976
file:///Users/jbussel/Desktop/CV/JB CV Articles/Puga 2011 Nat Immunol - B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen.pdf
173. Klaassen RJ, Mathias SD, Buchanan G, Bussel JB, Deuson J, Young NL, Collier A, Bomgaars L, Blanchette V.
Pilot Study of the Effect of Romiplostim on Child Health-Related Quality of Life (HRQoL) and Parental Burden in Immune Thrombocytopenia (ITP). Ped Blood & Cancer, 2012; 58(3): 395-8.
https://www.ncbi.nlm.nih.gov/pubmed/21910213 file:///Users/jbussel/Desktop/CV/JB CV Articles/Klaassen Peds Blood & Cancer 12 - Romiplostim on Child HRQOL and parental burden in ITP.pdf
174. Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT. Thrombopoietin receptor agonist therapy in
primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol. 2012; 25(1): 65-74. https://www.ncbi.nlm.nih.gov/pubmed/21841770
file:///Users/jbussel/Desktop/CV/JB CV Articles/Boiocchi 2012 Modern Pathology - Thrombopoietin receptor agonist therapy in primary ITP is associated with bone marrow hypercellularity and mild reticulin fibrosis.pdf
175. Despotovic JM, Lambert MP, Herman JH, Gernsheimer TB, McCrae KR, Tarantino MD, Bussel JB. Anti-D Immune
Globulin for the Treatment of Immune Thrombocytopenia: Consensus and Controversy. Transfusion, 2012; 52(5):
1126-1136. https://www.ncbi.nlm.nih.gov/pubmed/21981825 file:///Users/jbussel/Desktop/CV/JB CV Articles/Despotovic 2012 Transfusion - RhIG for the tx of ITP consensus and controversy.pdf
176. Arnason J, Campigotto F, Neuberg D, and Bussel JB. Abnormalities in IgA and IgM are associated with treatment
resistant ITP. Blood, 2012; 119(21): 5016-20. https://www.ncbi.nlm.nih.gov/pubmed/22490683
file:///Users/jbussel/Desktop/CV/JB CV Articles/Arnason Blood 2012 abnormalities in IgA and IgM are associated with treatment-resistant ITP.pdf
177. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In
Vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood, 2012; 119(17): 4066-72. https://www.ncbi.nlm.nih.gov/pubmed/22294727
file:///Users/jbussel/Desktop/CV/JB CV Articles/Psaila Blood 2011 - In vivo effects of eltrombopag on platelet function in immune thrombocytopenia- no evidence of platelet activiation.pdf
178. Feng X, Scheinberg P, Samsel L, Rios O, Chen J, McCoy JP, Ghanima W, Bussel JB, Young NS. Decreased plasma cytokines associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. Journal of Thrombosis and Hemostasis, 2012;(8): 1616-23. https://www.ncbi.nlm.nih.gov/pubmed/22537155
file:///Users/jbussel/Desktop/CV/JB CV Articles/Feng 2012 JTH - Decreased plasma cytokines are associated with low plt counts in aplastic anemia and ITP.pdf
179. Josephson CD, Granger S, Assman SF, Castillegjo M, Strauss RG, Slichter SJ, Steiner M, Journeycake J, Thronburg CD, Bussel JB, Grabowski EF, Neufeld EJ, Savage W, Sloan SR. Bleeding Risks Are Higher In Children versus Adults Given Prophylactic Platelet Transfusions for Treatment-Induced Hypoproliferative Thrombocytopenia. Blood, 2012; 120(4): 748-60. https://www.ncbi.nlm.nih.gov/pubmed/22538854
file:///Users/jbussel/Desktop/CV/JB CV Articles/Josephson Blood 2012 - Bleeding risks are higher in children versus adults given prophylactic plt tx for treatment-induced hypoproliferative thrombocytopenia.pdf
180. Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles SW, Godeau B, Kanter J, Neufeld EJ, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser ML, Cooper N, Bussel JB. Outcome at 5 years following response to rituximab therapy in children and adults with immune thrombocytopenia (ITP).
Blood, 2012; 119(25): 5989-95. https://www.ncbi.nlm.nih.gov/pubmed/22566601
file:///Users/jbussel/Desktop/CV/JB CV Articles/Patel Blood 2012 Outcomes 5 years after response to rituximab therapy in children and adults with ITP.pdf
181. Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, Bussel JB. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haem, 2012; 158(4): 539-47 https://www.ncbi.nlm.nih.gov/pubmed/22775462
file:///Users/jbussel/Desktop/CV/JB CV Articles/Cooper BJH 2012 Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in ITP.pdf
182. Ghanima W, Godeau B, Cines DB, Bussel JB. How I Treat Immune Thrombocytopenia (ITP): the choice between splenectomy or a medical therapy as a second-line treatment. Blood, 2012; 120(5):960-9. Updated, June, 2015. How I Treat: A Compendium for Practicing Hematologist 2nd Edition (Ed: Lowenberg, Berliner).
American Society Hematology, 2015; 203-213. file:///Users/jbussel/Desktop/CV/JB CV Articles/Ghanima 2012 Blood how I treat ITP.pdf https://www.ncbi.nlm.nih.gov/pubmed/22740443
183. Ghanima W, Lee SY, Barsam S, Miller A, Sandset PM, Bussel JB. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J. Haem,
2012; 158(6):811-4. https://www.ncbi.nlm.nih.gov/pubmed/22816787 file:///Users/jbussel/Desktop/CV/JB CV Articles/Ghanima 2012 BJH Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists..pdf
184. Li X, Zhong H, Bao W, Boulad N, Evangelista J, Haider MA, Bussel J, Yazdanbakhsh K. Defective Regulatory B cell Compartment in Patients with Immune Thrombocytopenia (ITP). Blood, 2012; 120(16): 3318-25.
https://www.ncbi.nlm.nih.gov/pubmed/22859611 file:///Users/jbussel/Desktop/CV/JB CV Articles/Li 2013 Blood Defective regulatory B-cell compartment in patients with ITP.pdf
185. Zhong H, Bao W, Li X, Miller A, Seery C, Haq N, Bussel JB, Yazdanbakhsh K. CD16+ monocytes control T cell
subset development in Immune Thrombocytopenia. Blood, 2012; 120(16):3326-35.
https://www.ncbi.nlm.nih.gov/pubmed/22915651 file:///Users/jbussel/Desktop/CV/JB CV Articles/Zhong Blood 2013 CD16+ monocytes control T-cell subset development in ITP.pdf
186. Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J. Haematol, 2013 Feb;160(4):538-46.
https://www.ncbi.nlm.nih.gov/pubmed/23278590 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 13 BJH Repeated short-term use of eltrombopag in patients with chronic ITP.pdf
187. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A. Safety and efficacy of eltrombopag
for treatment of chronic immune thrombocytopenia (ITP): results of the long-term, open-label EXTEND study. Blood, 2013; 121(3): 537-45. https://www.ncbi.nlm.nih.gov/pubmed/23169778
file:///Users/jbussel/Desktop/CV/JB CV Articles/Saleh Blood 2013 - Safety and efficacy of eltrombopag for treatmetn of chronic ITP EXTEND.pdf
188. Basciano PA, Bussel J, Hafeez Z, Christos PJ, Giannakakou P. The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). Br J Haematol, 2013;
160(2): 237-43. https://www.ncbi.nlm.nih.gov/pubmed/23157319 file:///Users/jbussel/Desktop/CV/JB CV Articles/Basciano 2013 BJH The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in ITP.pdf
189. Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, Cines DB, Cooper N, Godeau B, Greinacher A, Imbach P, Khellaf M, Klaassen RJ, Kuhne T, Liebman H, Mazzucconi MG, Newland A, Pabinger I, Tosetto A, Stasi R. Standardization of bleeding assessment in immune thrombocytopenia: report from the international working group. Blood, 2013;121(14):2596-606. https://www.ncbi.nlm.nih.gov/pubmed/23361904
file:///Users/jbussel/Desktop/CV/JB CV Articles/Rodeghiero Blood 2013 Standardization of bleeding assessment in ITP report from international working group.pdf
190. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol, 2013; 2013 May;161(3):411-23. https://www.ncbi.nlm.nih.gov/pubmed/23432528
file:///Users/jbussel/Desktop/CV/JB CV Articles/Kuter 2013 BJH Long-term treatment with romiplostim in patients with chronic ITP safety and efficacy.pdf
191. Psaila B, Bussel JB, Frelinger AL, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. J Thromb Haemost. 2013 May;11(5):1002-3. https://www.ncbi.nlm.nih.gov/pubmed/23496753
file:///Users/jbussel/Desktop/CV/JB CV Articles/Psaila JTH 2013 Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with ITP a rebuttal.pdf
192. Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA and Goldenberg DM. Subcutaneous injections of low-dose anti-CD20 veltuzumab are active in relapsed immune thrombocytopenia: a phase I study. Br J Haem, 2013; Sep;162(5):693-701. https://www.ncbi.nlm.nih.gov/pubmed/23829485
file:///Users/jbussel/Desktop/CV/JB CV Articles/Liebman 2013 BJH low dose veltuzumab.pdf
193. Noris P, Favier R, Alessi MC, Geddis AE, Kunishima S, Heller PG, Giordano P, Niederhoffer KY, Bussel JB, Podda GM, Vianelli N, Kersseboom R, Pecci A, Gnan C, Marconi C, Auvrignon A, Cohen W, Yu JC, Iguchi A, Miller Imahiyerobo A, Boehlen F, Ghalloussi D, De Rocco D, Magini P, Civaschi E, Biino G, Seri M, Savoia A, Balduini CL. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood, 2013; 122(11):1987-9.
https://www.ncbi.nlm.nih.gov/pubmed/24030261 file:///Users/jbussel/Desktop/CV/JB CV Articles/Noris Blood 2013 ANKRD26.pdf
194. Izak M, Bussel JB. Contemporary treatment of immune thrombocytopenia. Expert Rev Hematol, 2013; 6(6): 697-
712. https://www.ncbi.nlm.nih.gov/pubmed/24083655 file:///Users/jbussel/Desktop/CV/JB CV Articles/Izak Expert Rev Hematol 2013 - Contemporary treatment of immune thrombocytopenia.pdf
195. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, Comerma L, Chorny A, Shan M, Xu W, Magri G, Knowles DM, Tam W, Chiu A, Bussel JB, Serrano S, Lorente JA, Bellosillo B, Lloreta J, Juanpere N, Alameda F, Baró T, de Heredia CD, Torán N, Català A, Torrebadell M, Fortuny C, Cusí V, Carreras C, Diaz GA, Blander JM, Farber CM, Silvestri G, Cunningham-Rundles C, Calvillo M, Dufour C, Notarangelo LD, Lougaris V, Plebani A, Casanova JL, Ganal SC, Diefenbach A, Aróstegui JI, Juan M, Yagüe J, Mahlaoui N, Donadieu J, Chen K, Cerutti A. Corrigendum: B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the
marginal zone of the spleen. Nat Immunol, 2014; 15(2): 205. file:///Users/jbussel/Desktop/CV/JB CV Articles/Puga 2013 Nat Immunol B cell-helper.pdf
196. Kucine N, Chastain KM, Mahler MB, and Bussel JB. Primary Thrombocytosis in Children. Haematologica,
2014; 99: 620-628. https://www.ncbi.nlm.nih.gov/pubmed/24688110 file:///Users/jbussel/Desktop/CV/JB CV Articles/Kucine 2014 Haematologica Primary Thrombocytosis in children.pdf
197. Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, Bussel JB. Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up. Haematologica. 2014 May;99(5):937-44. https://www.ncbi.nlm.nih.gov/pubmed/24463212
file:///Users/jbussel/Desktop/CV/JB CV Articles/Ghanima 2014 Haematologica Bone marrow fibrosis in 66 patients with ITP.pdf
198. Ramaswamy K, Hsieh L, Leven E, Thompson MV, Nugent D, Bussel JB. Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children. J Pediatr. 2014 Sep;165(3):600-
605. https://www.ncbi.nlm.nih.gov/pubmed/24857517 file:///Users/jbussel/Desktop/CV/JB CV Articles/Ramaswamy 2014 J Peds Thombopoietic agents for treatment of ITP in children.pdf
199. Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, Turenne IG, Patel VL, Basciano PA, Elstrom RL, Ghanima W. Rituximab and 3 dexamethasone cycles provide responses similar to splenectomy in women and those with Immune Thrombocytopenia less than 2 years duration. Haematologica. 2014
Jul;99(7):1264-71. https://www.ncbi.nlm.nih.gov/pubmed/24747949 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2014 Haematologica Rituximab and 3 dexamethasone cycles.pdf
200. Levine DN, Birkenheuer AJ, Brooks MB, Nordone SK, Bellinger DA, Jones SL, Fischer TH, Oglesbee SE, Frey K,
Brinson NS, Pazandak Peters A, Marr HS, Motsinger-Reig A, Gudbrandsdottir S, Bussel JB, Key NS. A novel canine model of immune thrombocytopenia: Has ITP gone to the dogs? Br J Haematol. 2014 Oct;167(1):110-20
https://www.ncbi.nlm.nih.gov/pubmed/25039744 file:///Users/jbussel/Desktop/CV/JB CV Articles/LeVine 2014 BJH - Novel Canine model.pdf
201. Greene LA, Chen S, Seery C, Imahiyerobo AA, Bussel JB. Beyond the Platelet Count: Immature Platelet Fraction and Thromboelastometry Correlate with Bleeding in Patients with Immune Thrombocytopenia (ITP). Br J Haematol. 2014 Aug;166(4):592-600.. https://www.ncbi.nlm.nih.gov/pubmed/24797389
file:///Users/jbussel/Desktop/CV/JB CV Articles/Greene 2014 BJH - Beyond platelet count - immature platelet fraction.pdf
202. Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. https://www.ncbi.nlm.nih.gov/pubmed/24802775
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2014 Blood - avatrombopag.pdf
203. Noris P, Biino G, Pecci A, Civaschi E, Savoia A, Seri M, Melazzini F, Loffredo G, Russo G, Bozzi V, Notarangelo LD, Gresele P, Heller PG, Pujol-Moix N, Kunishima S, Cattaneo M, Bussel J, De Candia E, Cagioni C, Ramenghi U, Barozzi S, Fabris F, Balduini CL. Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. Blood. 2014 Aug 7;124(6):e4-e10.
https://www.ncbi.nlm.nih.gov/pubmed/24990887 file:///Users/jbussel/Desktop/CV/JB CV Articles/Noris Blood 2014 - Platelet diameters in inherited thrombocytopenias.pdf
204. Noris P, Schlegel N, Klersy C, Heller PG, Civaschi E, Pujol-Moix N, Fabris F, Favier R, Gresele P, Latger-Cannard V, Cuker A, Nurden P, Greinacher A, Cattaneo M, De Candia E, Pecci A, Hurtaud-Roux MF, Glembotsky AC, Muñiz-Diaz E, Randi ML, Trillot N, Bury L, Lecompte T, Marconi C, Savoia A, Balduini CL, Bayart S, Bauters A, Benabdallah-Guedira S, Boehlen F, Borg JY, Bottega R, Bussel J, De Rocco D, de Maistre E, Faleschini M, Falcinelli E, Ferrari S, Ferster A, Fierro T, Fleury D, Fontana P, James C, Lanza F, Le Cam Duchez V, Loffredo G, Magini P, Martin-Coignard D, Menard F, Mercier S, Mezzasoma A, Minuz P, Nichele I, Notarangelo LD, Pippucci T, Podda GM, Pouymayou C, Rigouzzo A, Royer B, Sie P, Siguret V, Trichet C, Tucci A, Saposnik B, Veneri D; European Hematology Association – Scientific Working Group on Thrombocytopenias and Platelet Function Disorders. Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica. 2014 Aug;99(8):1387-94. https://www.ncbi.nlm.nih.gov/pubmed/24763399
file:///Users/jbussel/Desktop/CV/JB CV Articles/Noris Haematologica 2014 - analysis of 339 pregnancies.pdf
205. Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, Karpoff M, White MJ, Josefsson EC, Kile BT and Bussel JB. Effect of TPO receptor agonists on the apoptotic profile of platelets in patients with chronic ITP. Am J Heme, 2014; 89(12): E228-34. https://www.ncbi.nlm.nih.gov/pubmed/25132654
file:///Users/jbussel/Desktop/CV/JB CV Articles/Mitchell 2014 AJH - Effect of TPO receptor agonists on the apoptotic profile of platelets.pdf
206. Maglione PJ, Simchoni N, Black S, Radigan L, Overbey JR, Bagiella E, Bussel JB, Bossuyt X, Casanova JL, Meyts I, Cerutti A, Picard C, Cunningham-Rundles C. IRAK-4- and MyD88- deficiencies impair IgM responses against T-independent bacterial antigens. Blood, 2014; 124(24): 3561-71.
https://www.ncbi.nlm.nih.gov/pubmed/25320238 file:///Users/jbussel/Desktop/CV/JB CV Articles/Maglione 2014 Blood - IRAK-4.pdf
207. Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer 2015;62:208–213. https://www.ncbi.nlm.nih.gov/pubmed/25345874
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2015 Peds Blood & Cancer long-term use of romiplostim in children.pdf
208. Basciano PA, Matakas J, Pecci A, Civaschi E, Cagioni C, Bompiani N, Burger P, Christos P, Snyder JP, Bussel JB, Balduini CL, Giannakakou P, Noris P. "β-1 tubulin R307H SNP alters microtubule dynamics and affects severity of a hereditary thrombocytopenia" Journal of Thrombosis and Haemostasis, 2015; 13(4): 651-9.
https://www.ncbi.nlm.nih.gov/pubmed/25529050 file:///Users/jbussel/Desktop/CV/JB CV Articles/Basciano 2015 JournalofThrombosis_and_Haemostasis.pdf
209. Zhong H, Bussel J, Yazdanbakhsh K. In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in
patients with immune thrombocytopenia. Br J Haematol; 2015; 168(2): 274-83.
https://www.ncbi.nlm.nih.gov/pubmed/25252160 file:///Users/jbussel/Desktop/CV/JB CV Articles/Zhong 2015-British_Journal_of_Haematology In vitro TNF.pdf
210. Peerschke E, Panicker S, Bussel JB. Classical Pathway of Complement Activation in ITP: Inhibition by TNT003, a novel C1s inhibitor. Br J Haematol. 2015 Aug 25. https://www.ncbi.nlm.nih.gov/pubmed/26305671
file:///Users/jbussel/Desktop/CV/JB CV Articles/Peerschke 2015-British_Journal_of_Haematology.pdf
211. Topka S, Vijai J, Walsh MF, Jacobs L, Maria A Villano D, Gaddam P, Wu G, McGee RB, Quinn E, Inaba H, Hartford C, Pui CH, Pappo AS, Edmonson M, Zhang M, Stepensky P, Steinherz P, Schrader K, Lincoln A, Bussel J, Lipkin S, Goldgur Y, Harit M, Stadler ZK, Mullighan C, Weintraub M, Shimamura A, Zhang J, Downing JR, Nichols KE*, Offit K*. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLOS Genetics, 2015; 11(6): e1005262. doi:10.1371/journal.pgen.1005262.
https://www.ncbi.nlm.nih.gov/pubmed/26102509 file:///Users/jbussel/Desktop/CV/JB CV Articles/Topka 2015 PLOS genetics Germline ETV6.PDF
212. Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang, MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB. Effects of Eltrombopag on Platelet Count and Platelet Activation in Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia. Blood. 2015 Sep 10;126(11):1367-78.
https://www.ncbi.nlm.nih.gov/pubmed/26224646 file:///Users/jbussel/Desktop/CV/JB CV Articles/Gerrits 2015 Blood - Effects of eltrombopag on WAS.pdf
213. Liu Z-J, Bussel JB, Lakkaraja M, Ferrer-Marin F, Ghevaert C, Feldman HA, McFarland JG, Chavda C, Sola-
Visner M. Suppression of in vitro Megakaryopoiesis by Maternal Sera Containing anti-HPA-1a Antibodies. Blood, 2015; 126(10): 1234-6. https://www.ncbi.nlm.nih.gov/pubmed/26209661
file:///Users/jbussel/Desktop/CV/JB CV Articles/Liu 2015 Blood - Suppression of in vitro megakaryopoiesis.pdf
214. Bussel JB, Wang X, Lopez A, Eisen M. Case study of remission in adults with immune thrombocytopenia (ITP)
following cessation of treatment with the thrombopoietin (TPO) mimetic romiplostim. Hematology. 2015 Aug 7: 1-
6. https://www.ncbi.nlm.nih.gov/pubmed/26251926 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2015 Hematology - case study of remission in adults.pdf
215. Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Oct 24;386(10004):1649-58. https://www.ncbi.nlm.nih.gov/pubmed/26231455
file:///Users/jbussel/Desktop/CV/JB CV Articles/Grainger 2015 Lancet - PETIT 2.pdf
216. Bussel JB, Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayur KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. The Lancet Haematology, 2015; 2(8): e315-e325.
https://www.ncbi.nlm.nih.gov/pubmed/26688484 file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2015 Lancet Haematology - PETIT.pdf
217. Tarantino MD, Danese M, Klaassen RJ, Duryea J, Eisen M, Bussel JB. Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. Platelets. 2016 Mar 4:1-7.
https://www.ncbi.nlm.nih.gov/pubmed/26941022 file:///Users/jbussel/Desktop/CV/JB CV Articles/Tarantino 2016 Platelets - Hospitalizations in pediatric patients with immune thrombocytopenia in the United States.pdf
218. Kucine N, Viny AD, Rampal R, Berger M, Socci N, Viale A, Bussel JB, Levine RL, Rapaport F. Genetic Analysis of Five Children With Essential Thrombocytosis Identifies Mutations in Cancer-Associated Genes With Roles in Transcriptional Regulation. Haematologica, 2016; 101(6): e237-9.
https://www.ncbi.nlm.nih.gov/pubmed/26992943 file:///Users/jbussel/Desktop/CV/JB CV Articles/Kucine 2016 Haematologica - Genetic analysis essential thrombocytosis.pdf
219. Tarantino M, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomized, double blind, placebo-controlled study. Lancet, 2016; 388(10039): 45-54.
https://www.ncbi.nlm.nih.gov/pubmed/27103127 file:///Users/jbussel/Desktop/CV/JB CV Articles/Tarantino Lancet 2016 279 romi ped ITP phase 3.pdf
220. Lakkaraja M, Berkowitz RL, Vinograd CA, Manotas KC, Jin JC, Ferd P, Gabor J, Wissert M, Mcfarland JG, Bussel JB. Omission of Fetal Sampling in Treatment of Subsequent Pregnancies in Fetal-Neonatal Alloimmune Thrombocytopenia. Am J Obstet Gynecol, 2016; 215(4): 471.e1-9.
https://www.ncbi.nlm.nih.gov/pubmed/27131591 file:///Users/jbussel/Desktop/CV/JB CV Articles/Lakkaraja 2016 AJOG - Omission of Fetal Sampling.pdf
221. Lakkaraja M, Jin JC, Manotas KC, Vinograd CA, Ferd P, Gabor J, Wissert M, Berkowitz RL, McFarland JG and
Bussel JB. Blood Type A Mothers are More Likely to Develop Anemia During Antenatal Intravenous Immunoglobulin Treatment of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Transfusion, 2016;
56(10): 2449-54. https://www.ncbi.nlm.nih.gov/pubmed/27611703 file:///Users/jbussel/Desktop/CV/JB CV Articles/Lakkaraja 2016-Transfusion Blood group A mothers.pdf
222. Chapin J, Lee CS, Zhang H, Zehnder JL and Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J. Hematol, 2016; 91(9): 907-
11. https://www.ncbi.nlm.nih.gov/pubmed/27220625 file:///Users/jbussel/Desktop/CV/JB CV Articles/Chapin 2016 AJH Gender and Duration of disease.pdf
223. Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM. Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. Haematologica, 2016; 101(11): 1327-32. https://www.ncbi.nlm.nih.gov/pubmed/27515248
file:///Users/jbussel/Desktop/CV/JB CV Articles/Liebman 2016 Haematologica Comparison of 2 dosing schedules.pdf
224. Gudbrandsdottir S, Ghanima W, Nielsen CH, Feng X, Hasselbalch HC, Bussel J. Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). Platelets, 2016: Nov 7: 1-6. https://www.ncbi.nlm.nih.gov/pubmed/27819522
file:///Users/jbussel/Desktop/CV/JB CV Articles/Gudbrandsdottir 2016 Platelets - Effect of thrombopoietin receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia ITP.pdf
225. Winkelhorst D, Murphy MF, Greinacher A, Shehata N, Bakchoul T, Massey E, Baker J, Lieberman L, Tanael S, Hume H, Arnold DM, Baidya S, Bertrand G, Bussel J, Kjaer M, Kaplan C, Kjeldsen-Kragh J, Oepkes D, Ryan G. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood, 2017; 129(11): 1538-1547. https://www.ncbi.nlm.nih.gov/pubmed/28130210
226. Tsang HC, Bussel JB, Mathew S, Liu Y-C, Imahiyerobo A, Orazi A, Geyer JT. Bone Marrow Morphology and Disease Progression in Congenital Thrombocytopenia: A detailed clinicopathologic and genetic study of 8 cases. Mod Pathol. 2017 Apr;30(4):486-498 https://www.ncbi.nlm.nih.gov/pubmed/28059092
file:///Users/jbussel/Desktop/CV/JB CV Articles/Tsang Mod Path 2017 - Boneo marrow morphology.pdf
227. Kuter DJ, Konkle BA, Hamza TH, Uhl L, Assmann SF, Kiss JE, Kaufman RM, Key NS, Sachais BS, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland JG, Neufeld E, Bussel JB, Ortel TL. Clinical Outcomes in a cohort of patients with heparin-induced thrombocytopenia. Am J Hem, 2017; Aug;92(8):730-738. https://www.ncbi.nlm.nih.gov/pubmed/28388835
228. Orsini S, Noris P, Bury L, Heller PG, Santoro C, Kadir RA, Butta NC, Falcinelli E, Cid AR, Fabris F, Fouassier M, Miyazaki K, Lozano ML, Zuñiga P, Flaujac C, Podda GM, Bermejo N, Favier R, Henskens Y, De Maistre E, De Candia E, Mumford AD, Ozdemir NG, Eker I, Nurden P, Bayart S, Lambert MP, Bussel J, Zieger B, Tosetto A, Melazzini F, Glembotsky AC, Pecci A, Cattaneo M, Schlegel N, Gresele P. Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. The Surgery in Platelet disorders And Therapeutic Approach (SPATA) study. Haematologica. 2017; Jul;102(7):1192-1203.
https://www.ncbi.nlm.nih.gov/pubmed/28385783 file:///Users/jbussel/Desktop/CV/JB CV Articles/Kuter 2017-American_Journal_of_Hematology Clinical Outcomes of patients with HIT.pdf
229. Garabet L, Ghanima W, Jonassen CM, Skov V, Hoist R, Mowinckel M, Hasslebalc HC, Kruse TA, Thomassen M, Liebman H, Bussel JB, Sandset P. Effect of Thrombopoietin Receptor Agonists on Markers of Coagulation and P-selectin in Patients with Immune Thrombocytopenia. Platelets, 2017; Dec 7:1-7.
230. Kovanlikaya A, Tiwari P, Bussel JB. Imaging and Management of Fetuses and Neonates with Alloimmune
Thrombocytopenia. Pediatric Blood & Cancer, 2017; Dec;64(12).
231. Newland A, Lee EJ, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy, 2018; Jan; 10(1):9-25.
232. Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-
term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017 Dec 7;130(23):2527-2536.
233. Oved JH, Lee CSY, Bussel JB. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic
Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone. J Pediatr. 2017 Dec; 191:225-231.
234. Ghanima W, Boiocchi L, Lee CS, Feng X, Geyer JT, Gudbrandsdottir S, Orazi A, Junker P, Bussel JB. Immune
thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment. Platelets. 2018 Jan 2:1-7.
235. Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ,
Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. Am J Hematol. 2018 Jul;93(7):882-888.
236. Fassel H, Bussel JB, Roberts SS, Modak S. Romiplostim for Immune Thrombocytopenia in Neuroblastoma
Patients Receiving Chemotherapy. J Pediatr Hematol Oncol. 2018 Apr 20.
237. Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018 Jul;93(7):921-930.
238. Chiang SCC, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D,
Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, Scurlock AM, Zhang K, Bryceson YT, Bleesing J, Marsh RA. Screening for Wiskott-Aldrich syndrome by flow cytometry. J Allergy Clin Immunol. 2018 Jul;142(1):333-335.e8.
239. Guitton Z, Terriou L, Lega JC, Nove-Josserand R, Hie M, Amoura Z, Bussel JB, Hamidou M, Rosenthal E, Lioger
B, Chauveau D, Chaminade A, Magy-Bertrand N, Michel M, Audia S, Godeau B, Mahevas M. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology (Oxford). 2018 Aug 1;57(8):1432-1438.
240. Kucine N, Al-Kawaaz M, Hajje D, Bussel J, Orazi A. Difficulty distinguishing essential thrombocythaemia from
polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. Br J Haematol. 2018 May 16.
241. Goel R, Westblade LF, Kessler DA, Sfeir M, Slavinski S, Backenson B, Gebhardt L, Kane K, Laurence J, Scherr
D, Bussel J, Dumler JS, Cushing MM. Death from Transfusion-Transmitted Anaplasmosis, New York, USA, 2017. Emerg Infect Dis. 2018 Aug;24(8):1548-1550.
242. Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Sci Transl Med. 2018 Sep 12;10(458).
Reviews:
1. Rabellino, E. R., Goodwin, L., Bussel, J. B., et al.: Studies of human marrow megakaryocytes. Elsevier
Symposium, Megakaryocytes in vitro, Atlanta CDC. May, 1980, published, December 1981.
2. Morell, A., Skvaril, F., Imbach, P., Bussel, J. and Barandun, S.: IgG subclasses in idiopathic thrombocytopenic purpura. Published in the Proceedings of Meeting of the European Group for Immunodeficiencies, 1983.
3. Bussel, J. B.: Circulating anticoagulants: Physiologic and pathophysiologic. Hospital Practice; 18(2): 169-172,
179-183, 186, February 1983. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 83 Hospital Practice - Circulating anticoagulants.pdf https://www.ncbi.nlm.nih.gov/pubmed/6185409
4. Cunningham-Rundles, C. and Bussel, J. B.: Clinical uses of human immunoglobulin. Internal Med for the
Specialist p220-229, Jan. 1984. file:///Users/jbussel/Desktop/CV/JB CV Articles/Cunningham-Rundles 84 Internal Med for the Specialist - Clinical Uses of Human Immunoglobulin.pdf
5. Bussel, J. B.: New treatment of ITP. Newsletter of the Council on Thrombosis of the American Heart Association,
1984. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 83 Newsltr of Council on Thrombosis for AMA - New treatment of ITP.pdf
6. Bussel, J. B.: Reply to letter "Fc-depleted vs intact intravenous immunoglobulin in chronic ITP" in The J of Ped
105(4):677, 1984.
7. Kimberly, R. P., Bussel, J. B. and Hilgartner, M. W.: Letter to annals internal medicine entitled "AIDS-like immuno-logic abnormalities in patients receiving multiple blood transfusions and factor VIII concentrates" Annals of Internal Medicine; 100(6):915-6, 1984.
8. Bussel, J. B., and Cunningham-Rundles, C.: Intravenous usage of Gammaglobulin: Humoral immunodeficiency,
immune thrombocytopenic purpura, and newer indications. Cancer Investigation 3(4):361-366, 1985.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 85 Cancer Investigation - IV use of Gammaglobulin - Humoral immunodeficiency ITP and Newer indications.pdf https://www.ncbi.nlm.nih.gov/pubmed/4040795
9. Bussel, J. B.: Treatment with intravenous gammaglobulin: Part I: Use in Chronic ITP to avoid splenectomy; Part
II: Mechanism of action: Intravenous immunoglobulin in immunodeficiency syndromes and ITP. Ed: Webster, A.D.B., and Waters, A.H. Int Congress and Symposium Series. Pub: Roy Soc Med, London; 1985.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 85 Intl Congress and Symposium series - Treatment with IV gammaglobulin in ITP to avoid splenec.pdf
10. Bussel, J. B.: The role of IgG in ITP. Clinical Immunology Today, 1985.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 85 Clin Immunology Today - Use of IgG in ITP.pdf
11. Bussel, J.B. and Cunningham-Rundles, C.: The usage of intravenous gammaglobulin in the treatment of humoral
immunodeficiency disease and autoimmune hematologic disease. Rational Drug Therapy 18(7): 1-6, 1984.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 84 Rational Drug Therapy - IV gammaglobulin in trmnt of humoral immunodefic disease and aih disease.pdf https://www.ncbi.nlm.nih.gov/pubmed/6085405
12. Bussel, J. B.: Management of idiopathic thrombocytopenic purpura in childhood. New York State Journal of
Medicine 85:499-501, 1985. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 85 NY State journal of med - mgmt of itp in childhood.pdf https://www.ncbi.nlm.nih.gov/pubmed/2413411
13. Bussel, J. B.: New therapies for ITP and related hematologic disorders, Nat. Immunotherapy Info Network, 1:2,
1985.
14. Bussel, J. B.: Intravenous gammaglobulin therapy for immune cytopenias, antibody therapy 1:1-3, 1985.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 85 antibody therapy in contemp med - IVGG for immune cytopenias.pdf
15. Bussel, J. B.: Intravenous immune serum globulin in immune thrombocytopenia: Clinical results and biochemical
evaluation. Vox Sang. 49(1):44-50, 1985. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 85 Vox Sang - IVIG in ITP - clinical results and biochemical eval.pdf https://www.ncbi.nlm.nih.gov/pubmed/2416127
16. Bussel, J. B.: Therapy in cytopenia. Vox Sang., 51 Suppl 2: 69-73, 1986.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 86 Vox Sang - Therapy in Cytopenia.pdf
17. Bussel, J. B., Morell, A., Skvaril F.: IgG2 deficiency in autoimmune cytopenias. Monographs in Allergy; 20: 116-
8, 1986. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 86 Monographs in Allergy - IgG2 deficiency in autoimmune cytopenias.pdf https://www.ncbi.nlm.nih.gov/pubmed/3773901
18. Bussel, J. B.: Placebo-controlled trial treating neonates wit immunoglobulin prepared for intravenous use (IVIG).
Ped Infect. Dis. 1986.
19. Bussel, J. B.: Immunoglobulin therapy for autoimmune hemolytic anemia. J. Pediat. 108(6): 1043, 1986. https://www.ncbi.nlm.nih.gov/pubmed/2423667
20. Bussel, J. B.: Giuliano, M., LaGamma, E. F.: Prophylaxis of neonatal sepsis with intravenous gammaglobulin.
Clinical use of Intravenous Immunoglobulins. Academic Press Inc., 1986.
21. Bussel,J. B.: Use and avoidance of platelet transfusion in idiopathic thrombocytopenic purpura. Platelet transfusion therapy, 1986.
22. Bussel, J. B. and Abboud, M.: Autoimmune neutropenia of childhood. Critical Reviews in Pediatric Hematology,
7(1):37-51, 1987. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 87 Critical reviews in onc hem - autoimmune neutropenia of childhood.pdf https://www.ncbi.nlm.nih.gov/pubmed/3304676
23. Bussel, J. B. and Imbach, P.: Clinical treatment with and mechanism of action of intravenous immunoglobulin (IV
IgG). IN Idiopathic Thrombocytopenic Purpura - Proceedings of a Workshop, Pharmanual, 51-62, 1987
24. Bussel, J., and Haimi, J.: Immune neutropenia and hypersplenism. Current Therapy in Hem/Onc., Third Edition, 1987.
25. Bussel, J. B. and Hilgartner, M. W.: Intravenous immunoglobulin therapy of idiopathic thrombocytopenic purpura
in childhood and adolescence. Hematology/Oncology Clinics of North America 1(3):465-482, 1987.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 87 HemOnc Clinics of North America - IVIG therapy of ITP in childhood & adolescence.pdf https://www.ncbi.nlm.nih.gov/pubmed/2452151
26. Bussel, J. B.: Intravenous immunoglobulin therapy for the treatment of idiopathic thrombocytopenic
purpura. Progress in Hemostasis and Thrombosis. 8:108-126, 1987. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 87 Progress in Hemostasis & Thrombosis - IVIG Therapy for the tx of ITP.pdf https://www.ncbi.nlm.nih.gov/pubmed/3550893
27. Bussel, J. B.: Mechanisms of effect of intravenous gammaglobulin and chronic ITP, State of the art in idiopathic
thrombocytopenic purpura (ITP) of childhood, Padua. 109-114, 1987.
28. Hilgartner, M. W., and Bussel, J.: Use of intravenous gammaglobulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Amer J. Med. (Supplement) 83(4A):25-29, 1987.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Hilgartner 87 Amer J Med - Use of IVGG for treatment of autoimmune neutropenia of childhood and AIHA.pdf https://www.ncbi.nlm.nih.gov/pubmed/3118705
29. Bussel, J. B.: Intravenous immunoglobulin therapy of immune hematological disease, American Association of
Blood Banks. 99-100, 1988.
30. Bussel, J.: Management of infants of mothers with immune thrombocytopenic purpura. J. Pediatrics 113(3):497-
499, 1988. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 88 J Peds - Mgmt of infants of mothers with ITP.pdf https://www.ncbi.nlm.nih.gov/pubmed/3411395
31. Bussel, J., Cunningham-Rundles, C., Feldman, C. Horowitz, B.: Transmission of viral infection by preparations of
intravenous immunoglobulin. Plasma Ther Transfus. Technol., 9:193-205, 1988.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 88 Plasma Ther Transfus Technol - Transmission of viral infection by preps of IVIG.pdf
32. Bussel, J. B.: Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous
immune globulin infusion in patients with immune thrombocytopenic purpura. Allergy & Clinical Immunology. 84(4 pt. 2):566-77. 1989. https://www.ncbi.nlm.nih.gov/pubmed/2677093
33. Bussel, J. B., McFarland, J. G., Berkowitz, R.: Antenatal treatment of fetal alloimmune cytopenias. Blut. 59(1):136-
8. 1989. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 89 Blut - Antenatal treatment of FAIT cytopenias.pdf https://www.ncbi.nlm.nih.gov/pubmed/2752171
34. Bussel, J. B.: The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura, Clin Immuno and
Immunopatho 53:S147-S155, 1989. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 89 Clin Immun and Immunopath - Use of IVIG in ITP.pdf https://www.ncbi.nlm.nih.gov/pubmed/2477185
35. Blanchette VS, Sacher RA, Ballem PJ, Bussel JB, Imbach P. Commentary on the management of autoimmune
thrombocytopenia during pregnancy and in the neonatal period. Blut, 1989; 59(1): 121-3. https://www.ncbi.nlm.nih.gov/pubmed/2752167
36. Bussel, J. B.: Neonatal uses of IVIG. Ped Inf Diseases. 1990.
37. Bussel, J. B.: Treatment effects of Fc blockade on chronic ITP. Immunohemotherapy. 254-258. 1990.
38. Bussel, J. B.: Autoimmune thrombocytopenic purpura. Hematology/Oncology Clinics of North America. Vol
4.1:179-191. 1990. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 90 Hem onc clinics of north america - autoimmune thrombocytopenic purpura.pdf https://www.ncbi.nlm.nih.gov/pubmed/1690204
39. Bussel, J. B., McFarland, J. G., Berkowitz, R. L.: Antenatal management of fetal alloimmune and autoimmune
thrombocytopenia. Transfusion Medicine Reviews, 4(2):149-62. 1990.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 90 Transfusion Med Reviews - antenatal mgmt of FAIT and NAIT.pdf https://www.ncbi.nlm.nih.gov/pubmed/2134623
40. Bussel, J. B.: Intravenous gammaglobulin in the prophylaxis of late sepsis in very-low-birth-weight infants:
Preliminary results of a randomized, double-blind, placebo-controlled trial. Reviews of infectious diseases, 12:S457-S462. 1990. https://www.ncbi.nlm.nih.gov/pubmed/2194270
41. Bussel, J. B.: Thrombocytopenia in newborns, infants, and children. Pediatric Annals. 19(3):181-5, 188-90, 192-
3. 1990. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 90 Pediatris annals - thrombocytopenia in newborns infants & children.pdf https://www.ncbi.nlm.nih.gov/pubmed/2181390
42. Bussel, J. B., Kimberly, R., Clarkson, S., Nochman, R., Valinsky, J., Unkeless, J. C.: Infusion of a monoclonal
anti-FcR III in patients with refractory ITP. Neo-Adjuvant Chemotherapy. Vol 169: 883-90. 1990.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 88 - Neo-Adjuvant Chemotherapy - Infusion of a monoclonal anti-FcR III in patient with refractory ITP.pdf
43. Bussel, J.B.: The Use of Intravenous Immunoglobulin in Immune Cytopenias: NIH Consensus Development
Conference on Intravenous Immunoglobulin: Prevention and Treatment of Disease 1990.
44. Bussel, J. B.: Neonatal uses of IV immunoglobulin. Am J. Ped. Hem. Onc. 12(4):505-9. 1990. https://www.ncbi.nlm.nih.gov/pubmed/1704687
45. Reply Letters to NEJM, vol. 342, p.1843-1843, 1990.
46. Williams, C., Buskard, N., Bussel, J. B.: Plasma exchange, IVIG treatment and general therapeutic management
of immune thrombocytopenia. Current Studies In Hematology and Blood Transfusion. (57):131-51, 1990.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Williams 90 Current studies in hem & blood tx - plasma exchange in ITP.pdf https://www.ncbi.nlm.nih.gov/pubmed/2272199
47. Bussel, J. B.: Platelet immunology: fundamental and clinical aspects antenatal treatment of neonatal alloimmune thrombocytopenia with intravenous gammaglobulin. John Libbey Eurotext, Colloque Inserm 206: 287-295, 1991.
48. Bussel, J. B.: The use of intravenous immunoglublin in auto immune deficiency, Canary Islands Symposium
Springer-Verlag berica, S.A. 1991.
49. Bussel, J. B.: Familial thrombocytopenia with micromegakaryocytes: What is the defect in thrombopoiesis? Amer
Journ Ped Hemat/Onc 14(3):189-191, 1992. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 92 AJPHO - Familial thrombocytopenia with micromegakaryocytes.pdf https://www.ncbi.nlm.nih.gov/pubmed/1510185
50. Bussel, J. B. and Grabowski, E.: Coagulation disorders in children. Current Opinion in Pediatrics. 5:88-93, 1993.
https://www.ncbi.nlm.nih.gov/pubmed/8374631
51. Brown, S. M., Linden, J. V., Dracker, R., Bussel, J. B., Malavade, V., Karpartkin, M., Fitzpatrick, J. E., Reich, L. New York State Council on Human Blood and Transfusion Services, Transfusion Practices Committee, Wadsworth Center for Laboratories and Research, New York State Department of Health.: Guidelines for transfusion therapy of infants from birth to four months of age. June 1993.
52. Cunningham-Rundles, S., Chen, C., Bussel, J. B., Blankenship, C., Veber, M. B. Sanders-Laufer, D. Hinds, T.
Cervia, J.S. Edelson, P.: Human immune development: implications for congenital HIV infection. Annals of the N.Y. Academy of Sciences. 1993;693:20-34. https://www.ncbi.nlm.nih.gov/pubmed/8267264
53. Hirschman, S., Bussel, J. B., Peterson, P.: Acquired hypoprothrombinemia - lupus anticoagulant syndrome.
American Society of Clinical Pathologists Check Sample, Clinical Pathology 1994,32(3):23-23.
54. Menell, J., Bussel, J. B.: Antenatal Management of the Thrombocytopenias, in Fetal Drug Therapy ed Koren, G.in Perinatal Clinics of North America. 21(3);591-614. September 1994.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Menell 94 Fetal Drug Therapy in ped clin of north america - antenatal mgmt of the thrombocytopenias.pdf https://www.ncbi.nlm.nih.gov/pubmed/7982336
55. Coletti, D. E. Bussel, J. B., Peterson, P.: Hematologic changes in Down syndrome. American Society of Clinical
Pathologists, Check Sample, Hematology Diseases. 1995;37(7) 33-39.
56. Bussel J. B., Szatrowski, T. P.: Uses of Intravenous Gammaglobulin in Immune Hematologic Disease, Immunolog
Invest 24(1-2), 451-456, 1995. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 95 Immunological investigations - Uses of IVGG in immune hematologic disease.pdf https://www.ncbi.nlm.nih.gov/pubmed/7713605
57. George, D., Bussel, J. B.: Neonatal Thrombocytopenia in. Seminars in the Thrombosis and Hemostasis Sutor,
A. H., Thomas, K. B. Eds: Hemostases in childhood: 21(3):276-293, 1995.
file:///Users/jbussel/Desktop/CV/JB CV Articles/George 95 Seminars in T & H - Neonatal thrombocytopenia.pdf https://www.ncbi.nlm.nih.gov/pubmed/8588155
58. Udom-Rice, I. and Bussel, J: Fetal and Neonatal Thrombocytopenia. Blood Reviews, Haemostasis. 9:57-
64;1995. file:///Users/jbussel/Desktop/CV/JB CV Articles/Udom-Rice 95 - Blood Reviews - Fetal and Neonatal Thrombocytopenia.pdf https://www.ncbi.nlm.nih.gov/pubmed/7580391
59. Horowitz, B., Bussel, J. B., James, W.: Solvent/detergent treatment of intravenous gammaglobulin: Rhyme and
Reason. Immunoglobulin Therapy. Viral Transmission Safeguards. Postgraduate Institute for Medicine. Winter
1995. file:///Users/jbussel/Desktop/CV/JB CV Articles/Horowitz 95 postgrad inst for med - Immunoglobulin therapy viral transmission safeguards.pdf
60. Imbach, P., Blanchette, V., Burek-Kozlowska, A., Bussel, J.B., Gaedicke, G., Gianella-Borradori, Gugler, E. Hirt,
A., Imholz, B., McMillian, R., Morell, A., Newland, A., Nugent, D., Schoni, M.H., Wagner, H.P. Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr 1995 154 [9 Suppl 4]: S60-S64. https://www.ncbi.nlm.nih.gov/pubmed/8529713
61. Bussel JB. Fetal neonatal thrombocytopenia. Thrombosis & Haemostasis, 1995; 74(1): 426-8.
https://www.ncbi.nlm.nih.gov/pubmed/8578499
62. Bussel, J.B.: Immune Thrombocytopenia in Pregnancy: Autoimmune and Alloimmune. J of Reprod Immun; 37(1):35-61, 1997. https://www.ncbi.nlm.nih.gov/pubmed/9501289
63. Gurewitsch, E., Bussel, J.B.: Hospital Physician, Obstetrics and Gynology Board Review Manual title:
Thrombocytopenia in Pregnancy. Vol. 4(2):10-23; 1998
64. Bussel, J.B., Kaplan C. The Fetal and Neonatal Consequences of Maternal Alliommune Thrombocytopenia. Baillieres Clinical Haematology; Editor Eldor, A., Michiel, J.J. 11(2): 391-408, 1998. https://www.ncbi.nlm.nih.gov/pubmed/10097816
65. Shupski, D,W, Bussel, J.B.; Antenatal Treatment of Fetal Immune Thrombocytopenia: Fetal and Maternal
Medicine Reviews 10:1-9, 1998. file:///Users/jbussel/Desktop/CV/JB CV Articles/Skupski 98 Fetal & Maternal med review - Antenatal trtmnt of fetal immune thrombocytopenias.pdf
66. Bussel, J. B.: Introduction: Recent Advances in the Treatment of Idiopathic Trombocytopenic Purura: Seminars
in Hematology: 35(1) [Suppl 1]: 1-4, 1998. https://www.ncbi.nlm.nih.gov/pubmed/9523742
67. Scaradavou, A., Bussel, J. B.: Clinical Experience With Anti-D in the Treatment of Idiopathic Thrombocytopenic Purpura: Seminars in Hematology: 35(1) [Suppl 1]: 52-57, 1998. https://www.ncbi.nlm.nih.gov/pubmed/9523749
68. Simpson, K. N., Coughlin, C. M., Eron, J., Bussel, J. B.: Idiopathic Thrombocytopenic Purpura: Treatment
Patterns and an Analysis of Cost Associated With Intravenous Immunoglobulin and Anti-D Therapy. Seminars in Hematology: 35(1) [Suppl 1]: 58-64, 1998. https://www.ncbi.nlm.nih.gov/pubmed/9523750
69. Modak, S. I., Bussel, J. B.: Treatment of children with immune thrombocytopenia purpura: Are we closer to
resolving the dilemma? J Pediatrics:133(3);313-314, 1998. https://www.ncbi.nlm.nih.gov/pubmed/9738705
70. Engelfriet CP, Reesink HW, Bussel J, Godeau B, Bierling P, Panzer S, Grumayer-Panzer ER, Mayr WR, Neppert J, Taaning E, Minchinton R, Bowman JM. The treatment of patients with autoimmune thrombocytopenia with intravenous IgG anti-D. Vox Sang, 1999; 76(4): 250-5. https://www.ncbi.nlm.nih.gov/pubmed/10454936
71. Bennett, C.L., Weinberg, P.D., Golub, R.M. and Bussel, J.B.: The Potential for Treatment of idiopathic
Thrombocytopenic Purpura With Anti-D to Prevent Splenectomy: A Predictive Cost Analysis. Seminars in Hematology, (eds Young, N.S. and Beris, P.) 37(1 Suppl 1): 26-30, 2000. https://www.ncbi.nlm.nih.gov/pubmed/10676921
72. Bussel, JB, Kunicki TJ, Michelson, AD. Platelets: New understanding of platelet glycoproteins and their role in disease.
Hematology, 2000; 222-240. https://www.ncbi.nlm.nih.gov/pubmed/11701544
73. Bussel, J.B.: Neonatal Thrombocytopenia. Symposium Proceedings from the Xth National Congress of Neonatology in Turkey, 2000.
74. Kelton JG, Bussel JB. Idiopathic immune thrombocytopenic purpura: an update. Semin Hematol, 2000; 37(3):
219-21. Review. https://www.ncbi.nlm.nih.gov/pubmed/10942215
75. Bussel JB. Alloimmune Thrombocytopenia in the Fetus and Newborn. Seminars in Thrombosis and Hemostasis. 27(3);245-252, 2001. https://www.ncbi.nlm.nih.gov/pubmed/11446658
76. McCrae KR., Bussel JB., Mannucci KM., Remuzzi G., Cines DB. Platelets: An Update on Diagnosis and
Management of Thrombocytopenic Disorders. Hematology Review, 2001: 282-305. https://www.ncbi.nlm.nih.gov/pubmed/11722989
77. Zacharoulis S., Bussel JB. Hematologic Considerations in HIV-Infected Children and Adolescents. NY State
Guidelines, 2001; www.hivguidelines.org (accessed 4/1/05).
78. Bussel JB. Another Interaction of the FcR System with IVIG. Thrombosis and Haemostasis 2002; 88(6): 890-91. https://www.ncbi.nlm.nih.gov/pubmed/12529734
79. Bussel JB. Novel Approaches to Refractory Immune Thrombocytopenic Purpura. Elsevier Science Ltd., Blood
Reviews 16(1); 31-36, 2002. https://www.ncbi.nlm.nih.gov/pubmed/11913991 80. Ahner, R., Bussel, J.B.: Gestational thrombocytopenia: immune thrombocytopenic purpura in pregnancy.
Women’s Issues in Thrombosis and Hemostatis. 283-296, 2002.
81. Trivedi DH, Bussel JB. 21. Immunohematologic disorders. J Allergy Clin Immunol 2003; 111(2 Suppl): S669-76. Review. https://www.ncbi.nlm.nih.gov/pubmed/12592312
82. Bussel, JB: Fetal and Neonatal Cytopenias: What Have We Learned? Amer J. Perinatology, 2003; 20(8):
425-431. https://www.ncbi.nlm.nih.gov/pubmed/14703590 83. Bolton-Maggs, P, Tarantino, M, Buchanan, G, Bussel, JB, and George, J.: The Child with ITP: Is
Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion From the 2002 ASPH/O Meeting – A Review. J of Peds Hem Onc, 2004; 26(2): 146-151. https://www.ncbi.nlm.nih.gov/pubmed/14767210
84. Schwartz, J and Bussel, JB: Anti-CD40L: Biology and Therapy in ITP. Blood, 2004; 103: 1178-1179.
http://www.bloodjournal.org/content/bloodjournal/103/4/1178.full.pdf
85. Cooper N, Bussel JB. The pathogenesis of ITP in adults and children. British Journal of Haematology, 2006; 133(4): 364-74. https://www.ncbi.nlm.nih.gov/pubmed/16643442
86. Bussel JB, Tarantino M. Review of Therapies for Immune Thrombocytopenic Purpura. Semin Hematol, 2006;
43 (suppl 5): S1-S2. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2006 Sem Hem - Review of Therapies for ITP.pdf https://www.ncbi.nlm.nih.gov/pubmed/16815344
87. Bussel JB. When are platelets just platelets? Blood, 2006; 107: 3426-27.
http://www.bloodjournal.org/content/bloodjournal/107/9/3426.1.full.pdf
88. Bussel JB. Treatment of Immune Thrombocytopenic Purpura in Adults. Semin Hematol, 2006; 43 (suppl 5):
S3-S10. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2006 Sem Hem - treatment of ITP in adults.pdf https://www.ncbi.nlm.nih.gov/pubmed/16815346
89. Bussel JB, Giulino L, Lee S, Sandborg C, Patel VL, and Stiehm ER. Update on Therapeutic Monoclonal
Antibodies. Elsevier Press. Curr Probl Pediatr Adolesc Health Care, 2007; 37(4): 118-35. https://www.ncbi.nlm.nih.gov/pubmed/17434008
90. Psaila B and Bussel JB. IVIg in ITP: no role for cytokines? Blood, 2007; 109(1): 4-5.
https://doi.org/10.1182/blood-2006-10-050906
91. Bussel JB. Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigens. Transfusion, 2007; 47(1): 6-7. https://www.ncbi.nlm.nih.gov/pubmed/17207223
92. Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol, 2007;
136(3): 366-78. https://www.ncbi.nlm.nih.gov/pubmed/17233844
93. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am. 2007 21(4): 743-59, vii. https://www.ncbi.nlm.nih.gov/pubmed/17666288
94. Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates.
Blood reviews, 2008; 22 (1): 1-52. https://www.ncbi.nlm.nih.gov/pubmed/17981381
95. Andemariam B, Psaila B, Bussel JB. Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program; 2007:106-13. https://www.ncbi.nlm.nih.gov/pubmed/18024617
96. Psaila B, Bussel JB. Recent insights into chemotherapy-induced thrombocytopenia. Evolving Concepts in
Thrombocytopenia, 2007; expert column.
97. Psaila B, Bussel JB. Recent Advances in the Treatment of Immune Thrombocytopenic Purpura. Emerging Strategies for Managing Immune Thrombocytopenic Purpura, 2007; expert column.
98. Bussel JB. Novel thrombopoietic agents: preliminary activity, potential benefit. J Support Oncol, 2007; 5(suppl
2): 063-064. https://www.ncbi.nlm.nih.gov/pubmed/17550056
99. Godeau B, Provan D, Bussel JB. Immune thrombocytopenic purpura in adults. Curr Opin Hematol, 2007; 14(5): 535-556. https://www.ncbi.nlm.nih.gov/pubmed/17934364
100. Bussel JB, Cines DB. Introduction: Immune thrombocytopenic purpura. Curr Opin Hematol, 2007; 14(5): 510.
10.1097/MOH.0b013e3282ab991e 101. Andemariam B, Bussel J. New therapies for immune thrombocytopenic purpura. Curr Opin Hematol, 2007;
14(5): 427-31. https://www.ncbi.nlm.nih.gov/pubmed/17934347
102. Kalpatthi R, Bussel JB. Management of Refractory immune thrombocytopenic purpura. Current Opinion in
Pediatrics, 2008; 20: 8-16. https://www.ncbi.nlm.nih.gov/pubmed/18197033
103. Kobos R, Bussel JB. Overview of Thrombopoietic Agents in Treatment of Thrombocytopenia. Clinical
Lymphoma and Myeloma, 2008; 8(1): 33-43. file:///Users/jbussel/Desktop/CV/JB CV Articles/Kobos Clin Lymph Myeloma 08 Overview of TPO agents in Trtmnt of thrombocytopenia.pdf https://www.ncbi.nlm.nih.gov/pubmed/18501086
104. Bussel JB and Marks KM. How effective is eltrombopag for the treatment of thrombocytopenia in patients with
HCV infection? Nature Clinical Practice Gastroenterology & Hepatology, 2008; 5(8): 424-25. https://www.ncbi.nlm.nih.gov/pubmed/18607406
105. Psaila B and Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and
management. British Journal of Haem, 2008; 143(1): 16-26. file:///Users/jbussel/Desktop/CV/JB CV Articles/Psaila BJH 08 Refrac itp - current strategies.pdf https://www.ncbi.nlm.nih.gov/pubmed/18573111
106. Psaila B, Bussel JB. Fc receptors in immune thrombocytopenias: a target for immunomodulation? J Clin Invest,
2008; 118(8): 2677-81. file:///Users/jbussel/Desktop/CV/JB CV Articles/Psaila J Clin Invest 08 Fc Receptors in immune thrombocytopenias.pdf https://www.ncbi.nlm.nih.gov/pubmed/18654670
107. Levy B, Arnason JE, Bussel JB. The use of second generation thrombopoietic agents for chemotherapy
induced thrombocytopenia. Current Opinion in Oncology, 2008; Nov;20(6):690-6.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Levy Curr Opin Onc 08 Use of 2nd gen tpo agents in chem-induced thrombocytopenia.pdf https://www.ncbi.nlm.nih.gov/pubmed/18841052
108. Cohn CS, Bussel JB. Romiplostim: a second-generation thrombopoietin agonist. Drugs Today, 2009
Mar;45(3):175-88. https://www.ncbi.nlm.nih.gov/pubmed/19436840
109. Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost, 2009; 7 Suppl 1: 253-7. https://www.ncbi.nlm.nih.gov/pubmed/19630811
110. Bussel JB. Therapeutic approaches to secondary immune thrombocytopenic purpura. Semin Hematol. 2009
Jan;46(1 Suppl 2):S44-58. Review. https://www.ncbi.nlm.nih.gov/pubmed/19245934
111. Bussel JB. The changing landscape of secondary ITP: introduction. Semin Hematol. 2009 Jan;46(1 Suppl 2):S1. https://www.ncbi.nlm.nih.gov/pubmed/19245928
112. Bussel JB. Traditional and New Approaches to the Management of Immune Thrombocytopenia: Issues of
When and Who to Treat. Hematology/Oncology Clinics of North America, 2009; 23(6): 1329-41. https://www.ncbi.nlm.nih.gov/pubmed/19932437
113. Bussel JB. Update on eltrombopag for ITP. Oncology, 2009; 23(13): 1177-8
https://www.ncbi.nlm.nih.gov/pubmed/20043469
114. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP Syndrome: a diverse set of disorders with different
immune mechanisms. Blood, 2009; Jun 25;113(26):6511-21. file:///Users/jbussel/Desktop/CV/JB CV Articles/Cines Blood 09 - ITP syndrome.pdf https://www.ncbi.nlm.nih.gov/pubmed/19395674
115. Bussel JB, Sola-Visner M. Current approaches to the evaluation and management of the fetus and neonate
with immune thrombocytopenia. Semin Perinatol. 2009 Feb;33(1):35-42. https://www.ncbi.nlm.nih.gov/pubmed/19167580
116. Cooper N and Bussel JB. Long-term Impact of Rituximab for Childhood Idiopathic Thrombocytopenic Purpura.
Current Rheumatology Reports, 2010; 12(2): 94-100. https://www.ncbi.nlm.nih.gov/pubmed/20425017
117. Fernandez-Cruz E, Kaveri SV, Peter HH, Durandy A, Cantoni N, Quinti I, Sorensen R, Bussel JB, Danieli MG, Winkelmann A, Bayry J, Käsermann F, Späth P, Helbert M, Salama A, van Schaik IN, Yuki N. 6th International immunoglobulin symposium: poster presentations. Clin Exp Immunol 2009; 158 Suppl 1: 60-7. https://www.ncbi.nlm.nih.gov/pubmed/19883425
118. Bussel JB. Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematol Oncol Clin North Am, 2009; (6): 1329-41. Review. https://www.ncbi.nlm.nih.gov/pubmed/19932437
119. Grainger JD, Bolton-Maggs PHB, Godeau B, Bussel JB, Donato H, Elalfy M, Hainmann I, Matzdorff A, Muller-
Beissenhirtz H, Rovo A, Tichelli A. Diagnosis and management of chronic ITP: Comments from an ICIS expert
group. Annals of Hematology, 2010; 89 (suppl 1): S11-17. file:///Users/jbussel/Desktop/CV/JB CV Articles/Grainger 2010 Ann Hematol - Diagnosis and management of chornic ITP - comments from ICIS expert group.pdf https://www.ncbi.nlm.nih.gov/pubmed/20449748
120. Rabin DU, Kuter DJ, Liebman HA, Bussel JB. What do healthcare providers ask their patients with immune
thrombocytopenia? Am J Hematol, 2010; 85(8): 629-31. file:///Users/jbussel/Desktop/CV/JB CV Articles/Rabin AJH 2010 - What do providers ask their patients.pdf https://www.ncbi.nlm.nih.gov/pubmed/20658595
121. Ghanima W, Bussel JB. Thrombopoietic agents in immne thrombocytopenia. Semin Hematol, 2010; 47(3): 258-
65. Review. file:///Users/jbussel/Desktop/CV/JB CV Articles/Ghanima 10 Semin Hematol - Thrombopoietic agents in ITP.pdf https://www.ncbi.nlm.nih.gov/pubmed/20620437
122. Bussel JB, Kuter DJ (Guest Editors). New Thrombopoietic Agents: introduction. Semin Hematol, 2010; 47(3):
211. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2010 Semin Hematol - New Thrombopoietic agents introduction.pdf https://www.ncbi.nlm.nih.gov/pubmed/20620430
123. Vinograd CA, Bussel JB. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective.
Haematologica, 2010; 95(11): 1807-11 file:///Users/jbussel/Desktop/CV/JB CV Articles/Vinograd Haematologica 2010 - antenatal treatment of FAIT.pdf https://www.ncbi.nlm.nih.gov/pubmed/21037327
124. Meyer R. Bussel JB. Consider thrombotic microangiopathy in pediatric and hematopoietic stem cell transplant
patients. Oncology (Williston Park), 2011; Sept;25(10): 920-1; 924. https://www.ncbi.nlm.nih.gov/pubmed/22010389
125. Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for
fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev. 2011 May 11;(5):CD004226. Review.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Rayment 2011 Cochrane library - Antenatal interventions for fetomaternal alloimmune thrombocytopenia review.pdf https://www.ncbi.nlm.nih.gov/pubmed/21563140
126. Bussel JB., Cines DB. Avoiding intuxication. Blood, 2012; 119(16): 3648-9.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel Blood 2012 - Avoiding Intuxication.pdf https://www.ncbi.nlm.nih.gov/pubmed/22517870
127. Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Hematol, 2012; 19(5): 392-8.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Basciano 2012 Current Opinion in Hematology - Thrombopoietin-receptor agonists.pdf https://www.ncbi.nlm.nih.gov/pubmed/22872157
128. Mitchell WB, Bussel JB. How low can you go? Blood. 2013 Jun 13;121(24):4817-8.
file:///Users/jbussel/Desktop/CV/JB CV Articles/Mitchell Blood 13 How low can you go.pdf https://www.ncbi.nlm.nih.gov/pubmed/23766459
129. Bussel JB, McFarland JG. Modified antibody in fetal alloimmunization. Blood. 2013 Jul 18;122(3):303-4
https://www.ncbi.nlm.nih.gov/pubmed/23869072
130. Terrell D, George JN, Bussel JB, Lyons RM, Pullarkat V, Redner RL, Selleslag D, Nie K, Woodard P. Self-Administration of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP). Community Oncology, 2013;10: 285-292.
131. Bussel JB, Lakkaraja M. Thrombopoietic agents: There is still much to learn. Presse Med. 2014; 43: e69–e78
file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2014 Presse Med TPO agents.pdf https://www.ncbi.nlm.nih.gov/pubmed/24680422
132. Tsai C-H, Bussel J, Imahiyerobo A, Sandler SL, Ogunnaike BA. Platelet count control in immune thrombocytopenic purpura patient: optimum romiplostim dose profile. The International Federation of Automatic Control, Cape Town, South Africa,19th World Congress, 2014: 11800-11805.
133. Cooper N, Bussel JB, Cotter F. The coming of age of the megakaryocyte-platelet. Br J Haematol, 2014;
165(2): 161-2. https://www.ncbi.nlm.nih.gov/pubmed/24690043
134. Izak M, Bussel JB. Management of thrombocytopenia. F1000Prime Reports 2014, 6:45. https://www.ncbi.nlm.nih.gov/pubmed/24991422
135. Bussel JB. The new thrombopoietic agenda: Impact on leukemias and MDS. Best Practice & Research Clincial
Haematology, 2014; 27(3-4): 288-92. https://www.ncbi.nlm.nih.gov/pubmed/25455280
136. Mitchell WB, Bussel JB. Thrombopoietin Receptor Agonists: A Critical Review. Semin Hematol, 2015; 52(1): 46-52. https://www.ncbi.nlm.nih.gov/pubmed/25578419
137. Lewin S, Bussel JB. Review of Fetal and Neonatal Immune Cytopenias. Clinical Advances in Hematology &
Oncology, 2015; 13(1): 35-43. file:///Users/jbussel/Desktop/CV/JB CV Articles/Lewin 2015 Clinical Advances in Hem Onc - Review of Fetal and Neonatal Immune Cytopenias.pdf https://www.ncbi.nlm.nih.gov/pubmed/25679972
138. Bussel JB. What do we know about intracranial hemorrhage in fetal and neonatal alloimmune
thrombocytopenia? Transfusion, 2016; 56(1): 17-18. https://www.ncbi.nlm.nih.gov/pubmed/26756707
139. Jain A, Bussel J. Thrombocytopenia in Children. Monograph on Platelet Disorders, 2016; 10: 107-114.
140. Bussel JB, Cooper N. Immune thrombocytopenia: a need for assisted suicide. Br J. Haematol, 2017; 176(2):
154. file:///Users/jbussel/Desktop/CV/JB CV Articles/Bussel 2016 BJH Immune thrombocytopenia a need for assisted suicide.pdf https://www.ncbi.nlm.nih.gov/pubmed/27879988
141. Bussel JB, Lee E-J. TPO for ITP in Pregnancy. Blood. 2017; 130(9):1073-1074.
142. Despotovic JM, Bussel JB. IVIg and FcγRIIb in kids with ITP: individualizing therapy. Blood. 2018 Aug
30;132(9):877-878.
Chapters:
1. Bussel, J. B., Schreiber, "ITP and Post-transfusion purpura". A. Chapter in Hematology: Basic Principles And Practice. Churchill Livingstone. 123:1485-1494, 1990.
2. Grodman, H. M., Bussel, J. B.: Hemorrhagic diseases due to circulating anticoagulants Chapter in Current Diagnosis, ed Conn. p. 630-634, 1991.
3. Bussel, J. B.: Neonatal immune thrombocytopenia. In Thrombocytopenia in childhood, Editors A. H. Sutor and K. B. Thomas, Editiones <Roche> Basel, Switzerland 1994;159-176.
4. Grodman, H. and Bussel J.: Intravenous Gammaglobulin, chpater in Acute rheumatic and immunologic diseases management of the critically ill patient. Edited by B.S. Mandell. Published by Marcel Dekker, 1994;559-579.
5. Bussel, J. B., Schreiber, A. D.: Immune Thrombocytopenic Purpura, Neonatal Alloimmune Thrombocytopenia and Post-Transfusion Purpura. in Hematology: Basic Principles and Practice. Editors Hoffman, R., Benz, E.J., Shattil, S., Furie, B. Cohen, H. J., Silberstein, L. E. 2nd Edition, Chapter 125:1849-1870, 1995.
6. Bussel, J. B., Corrigan, J. J.: Platelet and Vascular Disorders, in Blood Diseases of Infancy and Children. Editors Miller, D. R., Baehner, R. L. 7th Edition, Chapter 22:866-923, 1995.
7. Skupski, D., Wolf, C., Bussel, J. B.: Fetal and perinatal transfusion therapy. Clinical Practice of Transfusion Medicine. 3rd Edition. Edition, Edited by Lawrence D. Petz, S. N. Swisher, S. Kleinman, R. Spence, R. G. Strauss. Chapter 28;607-631, 1995. Article
8. Rivlin, K., Bussel, J. B.: Neonatal Hemostasis and Thrombosis, Chapter in Textbook Intensive Care of the Fetus and Neonate, edited by Alan R. Spitzer. Section XV11, p.1098, 1996.
9. Bussel, J.B.: IVIG Treatment of Immune Cytopenias.chapter in Intravenous Immunoglobulins in Clinical Practice
Lee, M., Strand, V.eds: 1998.
10. Bussel, J. B.: Fetal Hematology. Chapter in Fetal Disorders: Diagnosis and Management. Publ Wiley-Liss, Inc.: 7;167-173, 1999.
11. Sapp, M., Bussel, J.B.: Immune Haemolytic Anaemias. Pediatric Hematology, 2nd Edition (Lilleyman, J.S., Hann, I.M., Blanchette, V.S, eds). Churchill Livingstone, 1999.
12. Bussel, J. B., Cines, D.: Immune Thrombocytopenic Purpura, Neonatal Alloimmune Thrombocytopenia and Post-Transfusion Purpura. in Hematology: Basic Principles and Practice. Editors Hoffman, R., Benz, E.J., Shattil, S., Furie, B. Cohen, H. J., Silberstein, L. E. Churchill-Livingston, 3rd Edition: 126:2096-2114, 1999.
13. Bussel, J.B.: Splenectomy-Sparing Strategies for the Treatment and Long-Term Maintenance of Chronic Idiopathic (Immune) Thrombocytopenic Purpura. Chapter in Seminars in Hematology. eds Young, N.S. and Beris, P. 37(1 Suppl 1): 1-4, 1999.
14. Sapp MV, Bussel, JB. Chapter 10 – Immune hemolytic anemias. In Lilleyman J, Hann I, Blanchette V (eds). Pediatric Hematology, second edition, 1999: 203-218.
15. Bussel, J.B.: Splenectomy-Sparing Strategies for the Treatment and Long-Term Maintenance of Chronic Idiopathic (Immune) Thrombocytopenic Purpura. Chapter in Seminars in Hematology. eds Young, N.S. and Beris, P. 36(4), Suppl 9, 1-4, 1999.
16. Bussel, J.B.: Thrombocytopenias. Chapter in Hemostasis & Thrombosis (a clinical guide). eds Goodnight, S and Hathaway,. McGraw-Hill. 8:76-87, 2000.
17. Bussel, J.B.: Immune Thrombocytopenia. Chapter in Hemostasis & Thrombosis (a clinical guide). eds Goodnight,
S and Hathaway,. McGraw-Hill. 9:88-98, 2000.
18. Bussel, J.B.: New Developments in ITP Pertinent to the Use of Rituxan. Chapter in Seminars in Oncology. ed Rosen, S.T., 27(6), Suppl 12, 91-98, 2000.
19. Bussel, J.B.: FCR Blockade and ITP. Chapter in Seminars in Hematology. (Young, NS and Beris P, eds). W.B.
Saunders Co., Philadelphia, PA, 2000; 37(3):261-266. Article
20. Bussel, J.B. Thrombocytopenia. Chapter in “Fetal and Neonatal Secrets” eds Polin, R and Spitzer, A. Elsevier, 2001.
21. Bussel JB. Thrombophilia. Chapter in the Saunders manual of Pediatric Practice. Ed Finberg, 2002; 10(130):
500-506.
22. Ahner R., Bussel JB. Gestational Thrombocytopenia – Immune Thrombocytopenic Purpura in Pregnancy. Women’s Issues in Thrombosis and Hemostasis. (Brenner, B, Marder, VJ, Conard, J, eds). Martin Dunitz, 2002.
23. Hagani A., Bussel JB. The Child with a Bleeding Tendency. Chapter in the Saunders manual of Pediatric Practice.
Ed Finberg, 2002; 10(112): 439-442
24. Hagani A., Bussel JB. Hemophilia. Chapter in the Saunders manual of Pediatric Practice. Ed Finberg, 2002; 10(125): 487-491.
25. Kolb, A., Bussel, J.B.: Alloimmune thrombocytopenia. Platelets in Thrombotic and Non-Thrombotic Disorders.
(Gresele, P., Page, CP., Fuster, V., Vermlen, J., eds) Cambridge University Press, 2002; 3(38): 569-584.
26. Hagani A., Bussel JB. Platelet Disorders (Thrombocytopenia and Thrombocytopathy). Chapter in the Saunders Manual of Pediatric Practice. Ed Finberg, 2002; 10(128): 494-498.
27. Bussel JB. Immune Thrombocytopenia Purpura (ITP): Advances in Diagnosis and Management. Chapter in
Platelets. Ed Alan Michaelson. Academic Press 37; 547-555, 2002.
28. Bussel JB, Cines D: Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. Hematology: Basic Principles and Practice, 4th edition. (Hoffman R, Benz EJ, Shattil S, Furie B, Cohen HJ, Silberstein LE, and McGlave P, eds.) Elsevier Science, 2005.
29. Provan D, Bussel JB, Newland AC. Autoimmune Hematological disorders. Molecular Hematology, 2nd edition.
(Provan D, Gribben J, eds). Blackwell Publishing, 2005; 21: 251-266.
30. Chiu A, Tam W, Cines D, Bussel JB: Immune thrombocytopenia purpura: pathophysiology in patients with
persistent problems. Postgraduate Haematology 5th edition. (Hoffbrand AV, Catovsky D, Tuddenham EGD, eds). Blackwell Publishing Ltd., Oxford, England. 2005; 57: 937-944.
31. Jin DK, Bussel JB. Immune thrombocytopenia, post-transfusion thrombocytopenia, neonatal thrombocytopenia.
Clinical Hematology (Young N, Gerson S, High K, eds). Elsevier Science, 2005; 60: 781-90.
32. Provan D, Bussel JB, Newland AC. Autoimmune Hematological disorders. Molecular Hematology, 2nd edition. (Provan D, Gribben J, eds). Blackwell Publishing, 2005; 21: 251-266.
33. Bussel, JB. Congenital (Inherited, Familial) Thrombocytopenias (CTP). Thrombocytopenia (McCrae K, ed).
Taylor and Francis Publishing, 2006; 3: 55-74.
34. Bussel JB. Immune Thrombocytopenia Purpura (ITP) Platelets (Alan Michelson, ed.). Elsevier Press, 2006; 46: 831-847.
35. Bussel JB, Primiani A. Thrombocytopenia. Platelets in Cardiovascular and Hematologic Disorders: a clinical
handbook (Gresele, Fuster, Lopex, Page, Vermelyn, eds.). Cambridge University Press, UK, 2007; 10: 155-185.
36. Bussel JB, Cines D: Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. Hematology: Basic Principles and Practice, 5th edition. (Hoffman R, Benz EJ, Shattil S, Furie B, Silberstein LE, McGlave P, and Heslop H eds.) Elsevier Science, 2007; 138:
37. Mitchell WB and Bussel JB. IVIG Treatment for Hematologic Disorders. Intravenous Immunoglobulin therapy.
(Eds Alan Lazarus and John Semple). 2010, AABB press.
38. Renaud T and Bussel JB. Disorders of Platelets. Manual of Pediatric Hematology and Oncology, 5th edition. (Ed: Philip Lanzkowsky) Elsevier, 2010.
39. Wahlstrom J and Bussel JB. Chronic Refractory ITP. Immune Thrombocytopenia (ITP) in Children and Adults.
(Ed: Thomas Kuhne) UNI-MED Verlag AG (Bremen, London, Boston), 2010.
40. Bussel JB, Pinheiro MP. Eltrombopag. Hematopoietic Growth Factors in Oncology. G.H. Lyman, D.C. Dale (eds.), Cancer Treat Res, 2011; 157: 289-303. Review Article
41. McGuinn C, Bussel JB. Disorders of Platelets. Chapter 14. 6th edition of the Lanzkowsky Manual of Pediatric
Hematology and Oncology, 2015; 14: 239-279.
42. Mitchell WB, McGuinn C, Bussel JB. Platelets in the Critical Care Setting. Chapter 58. Comprehensive Critical Care: Pediatric, Second Edition, 2015. 789-98.